<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">BMC Psychiatry</journal-id><journal-title-group><journal-title>BMC Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28701225</article-id><article-id pub-id-type="pmc">5508614</article-id><article-id pub-id-type="publisher-id">1410</article-id><article-id pub-id-type="doi">10.1186/s12888-017-1410-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Takiguchi</surname><given-names>Kazuo</given-names></name><address><email>gomaokazuo@yahoo.co.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Uezato</surname><given-names>Akihito</given-names></name><address><email>uezapsyc@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Itasaka</surname><given-names>Michio</given-names></name><address><email>dianrang@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Atsuta</surname><given-names>Hidenori</given-names></name><address><email>hide.atta@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Narushima</surname><given-names>Kenji</given-names></name><address><email>kenji_narushima@tokyo-hmt.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Naoki</given-names></name><address><email>naoki_yamamoto@tmhp.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kurumaji</surname><given-names>Akeo</given-names></name><address><email>0724.psyc@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tomita</surname><given-names>Makoto</given-names></name><address><email>tomita.crc@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Oshima</surname><given-names>Kazunari</given-names></name><address><email>oshimapsyc@ybb.ne.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Shoda</surname><given-names>Kosaku</given-names></name><address><email>6395qcwd@jcom.home.ne.jp</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tamaru</surname><given-names>Mai</given-names></name><address><email>mahiru0422@hotmail.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nakataki</surname><given-names>Masahito</given-names></name><address><email>nktk@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Okazaki</surname><given-names>Mitsutoshi</given-names></name><address><email>okazakim@ncnp.go.jp</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ishiwata</surname><given-names>Sayuri</given-names></name><address><email>sayipsyc@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ishiwata</surname><given-names>Yasuyoshi</given-names></name><address><email>yasmpha@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Yasuhara</surname><given-names>Masato</given-names></name><address><email>yasuhara.mpha@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Arima</surname><given-names>Kunimasa</given-names></name><address><email>arimak@hosp.go.jp</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ohmori</surname><given-names>Tetsuro</given-names></name><address><email>ohmori@tokushima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nishikawa</surname><given-names>Toru</given-names></name><address><email>tnis.psyc@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1014 9130</institution-id><institution-id institution-id-type="GRID">grid.265073.5</institution-id><institution>Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, </institution><institution>Tokyo Medical and Dental University, </institution></institution-wrap>1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519 Japan </aff><aff id="Aff2"><label>2</label>Haryugaoka Hospital, Tensyoudan 11, Otsukimachi, Koriyama-shi, Fukushima, 963-0201 Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 2239</institution-id><institution-id institution-id-type="GRID">grid.417089.3</institution-id><institution>Psychiatry Department, </institution><institution>Tokyo Metropolitan Tama Medical Center, </institution></institution-wrap>2-8-29 Musashidai, Fuchu-shi, Tokyo, 183-8524 Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1014 9130</institution-id><institution-id institution-id-type="GRID">grid.265073.5</institution-id><institution>Clinical Research Center, </institution><institution>Medical Hospital of Tokyo Medical and Dental University, </institution></institution-wrap>1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519 Japan </aff><aff id="Aff5"><label>5</label>Ohmiya Kousei Hospital, Katayanagi 1, Minuma-ku, Saitama-shi, Saitama, 337-0024 Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1092 3579</institution-id><institution-id institution-id-type="GRID">grid.267335.6</institution-id><institution>Department of Psychiatry, Institute of Biomedical Sciences, </institution><institution>Tokushima University Graduate School, </institution></institution-wrap>3-18-15, Kuramoto, Tokushima, 770-8503 Japan </aff><aff id="Aff7"><label>7</label>Department of Psychiatry, National Center Hospital of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo, 187-8551 Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1014 9130</institution-id><institution-id institution-id-type="GRID">grid.265073.5</institution-id><institution>Department of Hospital Pharmacy, </institution><institution>Tokyo Medical and Dental University, </institution></institution-wrap>1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519 Japan </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>249</elocation-id><history><date date-type="received"><day>29</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">It has been reported that drugs which promote the <italic>N</italic>-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs.</p></sec><sec><title>Methods</title><p id="Par2">We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50&#x000a0;mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales.</p></sec><sec><title>Results</title><p id="Par3">D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower.</p></sec><sec><title>Conclusion</title><p id="Par4">It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity.</p></sec><sec><title>Trial registration</title><p id="Par5">UMIN Clinical Trials Registry (number <ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?recptno=R000000568">UMIN000000468</ext-link>). Registered 18 August 2006</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Schizophrenia</kwd><kwd>D-cycloserine</kwd><kwd>Glutamate</kwd><kwd>MR diffusion tensor imaging</kwd><kwd>Randomized</kwd><kwd>Placebo-controlled</kwd><kwd>Double-blind</kwd><kwd>Crossover</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003382</institution-id><institution>Core Research for Evolutional Science and Technology</institution></institution-wrap></funding-source><award-id>19390302</award-id><principal-award-recipient><name><surname>Nishikawa</surname><given-names>Toru</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Grant-in-Aid for Scientific Research (B)</institution></funding-source><award-id>21390330</award-id><principal-award-recipient><name><surname>Nishikawa</surname><given-names>Toru</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par41">Since <italic>N</italic>-Methyl-D-aspartate-type glutamate receptor (NMDA receptor) blockers, including phencyclidine and ketamine, were clarified to induce schizophrenia-like positive and negative symptoms and cognitive dysfunction in proportion to the potency, dysfunction of glutamate neurotransmission through the NMDA receptor in schizophrenia is assumed [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Accordingly, improvement of intractable schizophrenia symptoms by enhancing the NMDA receptor is expected, and it has been reported that drugs promoting the NMDA receptor function by stimulating the glycine modulatory site in this receptor improved negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par42">D-cycloserine (DCS) was clinically used as an antituberculosis drug, but its partial agonist action on the NMDA receptor glycine modulatory site was newly reported in 1989 [<xref ref-type="bibr" rid="CR5">5</xref>]. Since then, clinical studies of DCS aiming at improvement of schizophrenia symptoms by activating the NMDA receptor have been performed [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Compared with other usable agonists of the glycine modulatory site, the dose of DCS needed is lower because it readily passes though the blood-brain barrier, and the dose for psycho-neurologic disease is about 10&#x02013;30% of that for tuberculosis treatment, being readily clinically applicable. In several previous clinical studies, the optimum enhancement of the NMDA receptor function can be expected at about 50&#x000a0;mg/day. Although improvement of negative symptoms and cognitive dysfunction was reported, the results of the clinical studies were not consistent. It is possible that this inconsistency is due to heterogeneity of the clinical profile among patients analyzed. For example, early-onset schizophrenia is considered a more severe form with a poor prognosis [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] and the difference in the onset age may influence response to treatment, but these were not investigated in previous studies. In addition, recent imaging studies suggested that differences in the brain structure influence the treatment outcome (reviewed in [<xref ref-type="bibr" rid="CR23">23</xref>]). To address the influence of illness onset and the impact of altered brain structure, in this study, a placebo-controlled double-blind study of DCS was performed involving schizophrenia patients, and the efficacy and its association with the onset age and white matter integrity determined by diffusion tensor imaging were investigated.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par43">A randomized, placebo-controlled, double-blind, crossover design trial was performed at multicenters (Tokyo Medical and Dental University (TMDU), National Center of Neurology and Psychiatry, Tokushima University, Haryugaoka Hospital, Ohmiya Kousei Hospital). We described this clinical trial according to the CONSORT 2010 guidelines. A 2-week pre-observation period was set before initiation of drug administration to confirm eligibility of the subjects, followed by registration and randomized allocation. The subsequent 6, 3, and 6&#x000a0;weeks were established as the first, washout, and second phases, respectively. The rater, medical care staff, subjects, and their families did not know the allocated test drug, and DCS (50&#x000a0;mg/day) and placebo (PCB) were prepared with capsules indistinguishable from the appearance. To confirm the participants&#x02019; adherence to the study protocol, blood levels of DCS were measured by high performance liquid chromatography (HPLC) with electrochemical detection in the pre-observation period and at the end of the first and second phases. The subjects continued taking drugs that they usually took by the same administration method and dose throughout the study period.</p></sec><sec id="Sec4"><title>Inclusion and exclusion criteria</title><p id="Par44">The subjects were patients aged 20&#x000a0;years or older and below 70&#x000a0;years with schizophrenia meeting the diagnostic criteria of DSM-IV classification regardless of being in- or outpatients. Patients who received &#x02018;psychotherapy and formulated cognitive behavioral therapy excluding supportive psychotherapy&#x02019; within 12&#x000a0;weeks, those diagnosed with substance abuse (alcohol or drug) or substance dependence within 24&#x000a0;weeks based on the DSM-IV classification, those who received electroconvulsive therapy within 12&#x000a0;weeks, those with suicide attempt within 24&#x000a0;weeks, those with a past medical history of or complication by convulsive disease (epilepsy etc.), those with a past medical history of hypersensitivity to DCS and lactose, and those with severe organic disorder of the brain and physical symptoms were excluded. Participants who smoked were included but no individual information was obtained. Many participants were on benzodiazepines and they were maintained on the same dosage throughout the study. No participant was on clozapine.</p></sec><sec id="Sec5"><title>Psychometry</title><p id="Par45">One rater evaluated changes in neurologic manifestations using the Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) every 2&#x000a0;weeks from initiation of the first and second phases. The scores before initiation of each phase were used as baseline scores for each phase. Evaluations were also made before initiation and after completion of the first phase and after completion of the second phase using Brief Assessment of Cognition in Schizophrenia (BACS), Emotional Intelligence Scale (EQS), Global Assessment of Functioning (GAF), and the Japanese version of the Calgary Depression Scale for Schizophrenia (JCDSS). In addition, extrapyramidal symptoms were evaluated using the Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) and Abnormal Involuntary Movement Scale (AIMS). The scores before initiation of the first phase were used as baseline scores for both the first and second phase. Clinical testing of blood and urine were also performed to continuously observe the occurrence of adverse events to evaluate the safety.</p></sec><sec id="Sec6"><title>Image acquisition</title><p id="Par46">Magnetic resonance (MR) diffusion tensor imaging (DTI) was performed in the pre-observation period at TMDU. Imaging data were acquired on the 3.0&#x000a0;T MRI scanner (3.0&#x000a0;T Signa HDxt, GE Healthcare Japan). Diffusion tensor images were constructed of 2 sets of diffusion weight axial slice images (30 directions at b-value&#x000a0;=&#x000a0;1000, and a b-value&#x000a0;=&#x000a0;0&#x000a0;s/mm<sup>2</sup>, slice thickness&#x000a0;=&#x000a0;3.0&#x000a0;mm, slice gap&#x000a0;=&#x000a0;0, repetition time&#x000a0;=&#x000a0;14,000&#x000a0;ms, echo time&#x000a0;=&#x000a0;72.5, matrix 128&#x000a0;&#x000d7;&#x000a0;128 pixels, voxel resolution&#x000a0;=&#x000a0;1.875&#x000a0;&#x000d7;&#x000a0;1.875&#x000a0;&#x000d7;&#x000a0;3, Flip angle&#x000a0;=&#x000a0;90&#x000b0;, the number of slices scanned ranged 1600&#x02013;1800.).</p></sec><sec id="Sec7"><title>Tract based spatial statistics (TBSS)</title><p id="Par47">To reveal the white matter abnormality in schizophrenia, statistical analysis was performed using the FSL (FMRIB Software Library, FMRIB, Oxford, UK) software package including FDT (FMRIB&#x02019;s Diffusion Toolbox). First, imaging data were collected for the distortion and head motion, calculated by using the &#x0201c;eddy correct&#x0201d; function. A brain mask was made from the b&#x000a0;=&#x000a0;0 image to use brain extraction of tensor image, and then fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), radial diffusivity (RD) maps were calculated by using the &#x0201c;dtifit&#x0201d; function to fit tensor model. All parameters at each voxel were performed by voxel-wise statistics as follows.</p><p id="Par48">Tract based spatial statistics (TBSS) were applied on the common pseudoanatomical skeleton in which all subjects&#x02019; FA data were aligned to FMRIB58_FA standard &#x02013;space image, using nonlinear registration tool [<xref ref-type="bibr" rid="CR24">24</xref>]. And then atlas based region of interest (ROI) analysis was performed by using JHU DTI 81 labels atlas. This atlas included the 48 white matter tracts such as corpus callosum, fornix, and internal capsule. The voxel mean FA of these tracts was calculated in each subject.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par49">Statistical analysis was performed using the IBM SPSS Statistics software (version 23.0). The significance level was set at <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05. Multiple comparison was not taken into consideration.</p><sec id="Sec9"><title>Patient characteristics</title><p id="Par50">Difference between the DCS-first and PCB-first groups on age, age at onset, age at starting therapy, duration of illness, education, or CPZ equivalents were examined by Mann-Whitney U-test.</p></sec><sec id="Sec10"><title>Effect of treatment by time</title><p id="Par51">Three subscales of PANSS (positive symptoms (P), negative symptoms (N), and general psychopathology (G)) and 7 subscales of SANS (I, II, III, IV, V, summary score, and total score) were analyzed by 2-way repeated-measures of analysis of covariance (RM-ANCOVA) constructed of within-subject factors of treatment (DCS/PCB) and time (baseline, week 2, week 4, and week 6) and covariates of treatment order. Seven subscales of BACS (verbal memory (VM), digit sequencing task (DS), token motor task (TM), symbolic coding (SC), verbal fluency of category (VFC), verbal fluency of letter (VFL), and tower of London (TOL)) and 3 subscales of EQS (intrapersonal, interpersonal, and situational domains) were also analyzed using RM-ANCOVA with a within-subject factor of time (baseline and week 6). Furthermore, GAF, JCDSS, DIEPSS, and AIMS were also analyzed using RM-ANCOVA with a within-subject factor of time (baseline and week 6). If Mauchly&#x02019;s sphericity test was significant, then the Greenhouse-Geisser correction was applied.</p></sec><sec id="Sec11"><title>Correlation between DCS-effect and DTI white matter integrity</title><p id="Par52">To investigate whether or not the white matter integrity influences response to DCS, we first introduced a parameter &#x02018;DCS-effect&#x02019; which was defined by scores at DCS phase subtracted by those at PCB phase. DCS-effect is a value to indicate the net effect of DCS excluding placebo effect. Correlations between the tract FA values of the 48 brain regions and DCS-effects on PANSS, SANS, BACS, and EQS were analyzed using Pearson&#x02019;s correlation coefficient. Significance level for the correlation analysis was set <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01. Multiple comparison was not taken into consideration.</p></sec></sec><sec id="Sec12"><title>Secondary analysis: Onset age and DCS-effect</title><p id="Par53">To investigate whether or not the onset age influences response to DCS, patients were stratified by onset ages of &#x0003c;18&#x000a0;years (early-onset schizophrenia, EOS) or 18&#x000a0;years or older (non-early-onset schizophrenia, non-EOS), according to the generally accepted threshold for EOS [<xref ref-type="bibr" rid="CR25">25</xref>]. Of note, one non-EOS patient was traditionally-defined late-onset (45&#x000a0;years or older) schizophrenia.</p><p id="Par54">EOS (<italic>n</italic>&#x000a0;=&#x000a0;6) and non-EOS (<italic>n</italic>&#x000a0;=&#x000a0;30) were compared using multivariate analysis of covariance (MANCOVA) regarding the DCS-effects on subscales of PANSS (P, N and G), SANS (I-V, summary and total), BACS (VM, DS, TM, SC, VFC, VFL, and TOL) and EQS (intrapersonal, interpersonal, and situational domains) as dependent variables, onset age (EOS vs. non-EOS) as an independent variable, and treatment order as a covariate.</p></sec><sec id="Sec13"><title>Sample preparation and high-performance liquid chromatography (HPLC) with electrochemical detection</title><p id="Par55">The concentrations of DCS were quantitated by HPLC with electrochemical detection according to the method of Takahashi et al. [<xref ref-type="bibr" rid="CR26">26</xref>]. For this assay, the plasma samples provided by the patients were homogenized in 2 volumes of 10% trichloroacetic acid. The supernatants resulting from centrifugation of the homogenate at 14,500&#x000a0;g for 20&#x000a0;min at 4&#x000a0;&#x000b0;C were neutralized by 2&#x000a0;M imidazole and stored at &#x02212;80&#x000a0;&#x000b0;C until derivatization. An aliquot of each sample was derivatized with o-phthaldialdehyde (OPA) (nakalai tesque, Japan) for 2&#x000a0;min at room temperature. The derivatized sample was immediately applied to the HPLC system (HTEC-500; EICOM, Japan) and then analyzed on a on a SC-5ODS (&#x003c6;3.0&#x000a0;&#x000d7;&#x000a0;150&#x000a0;mm) with a pre-column. The separation column was operated at the constant flow rate of 0.5&#x000a0;ml/min at 30&#x000a0;&#x000b0;C. Mobile phase was 50% 50&#x000a0;mM phosphate buffer solution (pH&#x000a0;2.8) containing 5&#x000a0;mg/L disodium-ethylenediaminetetraacetic acid (EDTA) and 50% methanol. DCS was eluted in the mobile phase within 10&#x000a0;min.</p><p id="Par56">The presence of substantial plasma concentrations of DCS after the actual drug periods, but not the placebo periods, in each patient was verified.</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Patient characteristics</title><p id="Par57">Figure <xref rid="Fig1" ref-type="fig">1</xref> shows the CONSORT diagram for the trial. Forty-one of 42 patients met the criteria and were enrolled in the study. When they were randomly allocated to the DCS-first (DCS was administered in the first phase) and PCB-first (PCB was administered in the first phase) groups, 19 and 22 patients were included in the groups, respectively. Seventeen (89.5%) and 19 (86.4%) patients completed the clinical study in the DCS-first and PCB-first groups, respectively, a total of 36 patients (Table <xref rid="Tab1" ref-type="table">1</xref>). Five patients dropped out: 2 dropped out (1 each in the DCS-first and PCB-first groups) in the first treatment phase and 3 dropped out (1 and 2 in the DCS-first and PCB-first groups, respectively) in the second treatment phase. The reason for dropout was an adverse event (liver enzyme elevation) in 2 and poor compliance of hospital visit in 3. Both cases of adverse event occurred in the placebo phase.<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT flow of participants through the trial</p></caption><graphic xlink:href="12888_2017_1410_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>DCS-first group</th><th>PCB-first group</th><th>Total</th></tr></thead><tbody><tr><td>N (Male/Female)</td><td>17 (10/7)</td><td>19 (12/7)</td><td>36 (22/14)</td></tr><tr><td>Age (years)</td><td>48.4&#x000a0;&#x000b1;&#x000a0;16.1</td><td>40.1&#x000a0;&#x000b1;&#x000a0;10.7</td><td>44.0&#x000a0;&#x000b1;&#x000a0;14.0</td></tr><tr><td>Age at onset (years)</td><td>22.6&#x000a0;&#x000b1;&#x000a0;8.5</td><td>24.3&#x000a0;&#x000b1;&#x000a0;5.6</td><td>23.5&#x000a0;&#x000b1;&#x000a0;7.1</td></tr><tr><td>Age at starting therapy (years)</td><td>23.9&#x000a0;&#x000b1;&#x000a0;8.5</td><td>24.8&#x000a0;&#x000b1;&#x000a0;5.7</td><td>24.4&#x000a0;&#x000b1;&#x000a0;7.1</td></tr><tr><td>Duration of illness (years)</td><td>25.8&#x000a0;&#x000b1;&#x000a0;17.3</td><td>15.8&#x000a0;&#x000b1;&#x000a0;9.2</td><td>20.5&#x000a0;&#x000b1;&#x000a0;14.4</td></tr><tr><td>Education (years)</td><td>12.4&#x000a0;&#x000b1;&#x000a0;2.6</td><td>13.9&#x000a0;&#x000b1;&#x000a0;2.9</td><td>13.2&#x000a0;&#x000b1;&#x000a0;2.9</td></tr><tr><td>CPZ equivalents (mg/day)</td><td>777.5&#x000a0;&#x000b1;&#x000a0;614.8</td><td>871.3&#x000a0;&#x000b1;&#x000a0;618.0</td><td>827.0&#x000a0;&#x000b1;&#x000a0;609.5</td></tr></tbody></table><table-wrap-foot><p>
<italic>DCS</italic> D-cycloserine, <italic>PCB</italic> placebo, <italic>CPZ</italic> chlorpromazine. No significant difference was noted between the DCS-first and PCB-first groups on age, age at onset, age at starting therapy, duration of illness, education, or CPZ equivalents</p></table-wrap-foot></table-wrap>
</p><p id="Par58">The male:female ratio of the subjects who completed the clinical study was 61%:39%, the mean age was 44&#x000a0;years old, the mean age at the time of treatment initiation was 24.4&#x000a0;years old, and the mean duration of illness was 20.5&#x000a0;years. The mean years of education was 13.2&#x000a0;years, and average chlorpromazine (CPZ) equivalent of antipsychotic drugs they took was 827&#x000a0;mg/day. No significant difference was noted between the DCS-first and PCB-first groups on age, age at onset, age at starting therapy, duration of illness, education, or CPZ equivalents. (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par59">The blood DCS levels were measured in each phase and compared by analysis of variance. There was no difference between baseline and PCB phase, and a significant difference between baseline and DCS phase, indicating that participants were adherent with the study protocol.</p></sec></sec><sec id="Sec16"><title>Psychometrics</title><sec id="Sec17"><title>Effect of treatment by time</title><p id="Par60">No treatment by time effect was noted in any subscale of PANSS, SANS (Table <xref rid="Tab2" ref-type="table">2</xref>), BACS, or EQS (Table <xref rid="Tab3" ref-type="table">3</xref>). No treatment by time effect was noted in any of GAF, JCDSS, DIEPSS, and AIMS (data not shown).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Treatment by time effect of DCS on PANSS and SANS</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="8">Week within treatment phase</th><th>Analysis</th><th/></tr><tr><th/><th>Treatment</th><th colspan="2">Baseline</th><th colspan="2">Week 2</th><th colspan="2">Week 4</th><th colspan="2">Week 6</th><th colspan="2">treatment x time</th></tr><tr><th/><th/><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>F</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td colspan="12">PANSS</td></tr><tr><td>&#x02003;Positive</td><td>DCS</td><td>14.39</td><td>5.71</td><td>14.42</td><td>5.87</td><td>14.03</td><td>5.86</td><td>14.06</td><td>5.89</td><td>0.51</td><td>0.61</td></tr><tr><td/><td>PCB</td><td>14.72</td><td>5.79</td><td>14.19</td><td>5.46</td><td>14.11</td><td>5.16</td><td>13.97</td><td>5.62</td><td/><td/></tr><tr><td>&#x02003;Negative</td><td>DCS</td><td>20.47</td><td>7.12</td><td>20.19</td><td>6.97</td><td>20.19</td><td>6.64</td><td>19.86</td><td>7.04</td><td>0.37</td><td>0.69</td></tr><tr><td/><td>PCB</td><td>20.58</td><td>6.87</td><td>20.31</td><td>7.01</td><td>20.00</td><td>6.57</td><td>19.56</td><td>7.11</td><td/><td/></tr><tr><td>&#x02003;General</td><td>DCS</td><td>34.44</td><td>8.14</td><td>33.69</td><td>8.36</td><td>33.81</td><td>8.75</td><td>33.56</td><td>8.58</td><td>1.70</td><td>0.18</td></tr><tr><td/><td>PCB</td><td>35.22</td><td>8.11</td><td>34.56</td><td>7.78</td><td>33.97</td><td>7.26</td><td>33.83</td><td>8.48</td><td/><td/></tr><tr><td colspan="12">SANS</td></tr><tr><td>&#x02003;I</td><td>DCS</td><td>13.97</td><td>8.39</td><td>13.56</td><td>8.65</td><td>13.67</td><td>8.51</td><td>13.36</td><td>8.40</td><td>0.34</td><td>0.79</td></tr><tr><td/><td>PCB</td><td>14.03</td><td>8.25</td><td>13.86</td><td>7.88</td><td>13.17</td><td>7.81</td><td>13.44</td><td>7.95</td><td/><td/></tr><tr><td>&#x02003;II</td><td>DCS</td><td>7.92</td><td>4.92</td><td>7.39</td><td>5.06</td><td>7.31</td><td>4.83</td><td>7.11</td><td>4.89</td><td>0.44</td><td>0.72</td></tr><tr><td/><td>PCB</td><td>8.22</td><td>4.67</td><td>7.75</td><td>4.78</td><td>7.19</td><td>4.71</td><td>7.22</td><td>4.75</td><td/><td/></tr><tr><td>&#x02003;III</td><td>DCS</td><td>10.14</td><td>4.26</td><td>9.89</td><td>4.45</td><td>9.78</td><td>4.32</td><td>9.61</td><td>4.32</td><td>0.50</td><td>0.62</td></tr><tr><td/><td>PCB</td><td>10.00</td><td>3.92</td><td>9.67</td><td>4.24</td><td>9.61</td><td>4.32</td><td>9.78</td><td>4.18</td><td/><td/></tr><tr><td>&#x02003;IV</td><td>DCS</td><td>12.44</td><td>5.34</td><td>12.22</td><td>5.53</td><td>12.08</td><td>5.26</td><td>12.08</td><td>5.44</td><td>0.18</td><td>0.84</td></tr><tr><td/><td>PCB</td><td>12.50</td><td>5.01</td><td>12.33</td><td>5.35</td><td>12.14</td><td>5.16</td><td>12.47</td><td>5.36</td><td/><td/></tr><tr><td>&#x02003;V</td><td>DCS</td><td>5.97</td><td>3.61</td><td>5.61</td><td>3.63</td><td>5.44</td><td>3.39</td><td>4.94</td><td>3.43</td><td>0.66</td><td>0.58</td></tr><tr><td/><td>PCB</td><td>5.78</td><td>3.69</td><td>5.64</td><td>3.77</td><td>4.78</td><td>3.39</td><td>5.03</td><td>3.34</td><td/><td/></tr><tr><td>Summary</td><td>DCS</td><td>11.75</td><td>4.72</td><td>11.33</td><td>4.76</td><td>11.14</td><td>4.59</td><td>10.78</td><td>4.74</td><td>0.79</td><td>0.44</td></tr><tr><td/><td>PCB</td><td>11.42</td><td>4.76</td><td>11.39</td><td>4.56</td><td>10.83</td><td>4.58</td><td>10.89</td><td>4.59</td><td/><td/></tr><tr><td>Total</td><td>DCS</td><td>50.44</td><td>21.88</td><td>48.67</td><td>22.57</td><td>48.28</td><td>21.69</td><td>47.11</td><td>22.55</td><td>0.52</td><td>0.62</td></tr><tr><td/><td>PCB</td><td>50.53</td><td>20.81</td><td>49.25</td><td>20.70</td><td>46.89</td><td>20.42</td><td>47.94</td><td>20.95</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>PANSS</italic>, Positive and Negative Syndrome Scale; <italic>SANS</italic>, Scale for the Assessment of Negative Symptoms; <italic>SD</italic>, standard deviation; &#x02018;Baseline&#x02019; indicates Week 0 for the first phase and Week 9 (after 3&#x000a0;week washout period) for the second phase</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Treatment by time effect of DCS on BACS and EQS</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="4">Week within treatment phase</th><th>Analysis</th><th/></tr><tr><th/><th>Treatment</th><th colspan="2">Baseline</th><th colspan="2">Week 6</th><th colspan="2">treatment x time</th></tr><tr><th/><th/><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>F</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td colspan="8">BACS</td></tr><tr><td>&#x02003;VM</td><td>DCS</td><td rowspan="2">34.18</td><td rowspan="2">15.09</td><td>37.15</td><td>16.11</td><td>0.01</td><td>0.91</td></tr><tr><td/><td>PCB</td><td>37.15</td><td>16.04</td><td/><td/></tr><tr><td>&#x02003;DS</td><td>DCS</td><td rowspan="2">16.48</td><td rowspan="2">5.76</td><td>16.97</td><td>5.96</td><td>0.20</td><td>0.65</td></tr><tr><td/><td>PCB</td><td>17.58</td><td>5.84</td><td/><td/></tr><tr><td>&#x02003;TM</td><td>DCS</td><td rowspan="2">58.73</td><td rowspan="2">21.84</td><td>60.64</td><td>21.92</td><td>0.02</td><td>0.90</td></tr><tr><td/><td>PCB</td><td>63.33</td><td>20.69</td><td/><td/></tr><tr><td>&#x02003;SC</td><td>DCS</td><td rowspan="2">46.52</td><td rowspan="2">16.36</td><td>47.03</td><td>15.71</td><td>0.89</td><td>0.35</td></tr><tr><td/><td>PCB</td><td>48.42</td><td>16.21</td><td/><td/></tr><tr><td>&#x02003;VFC</td><td>DCS</td><td rowspan="2">15.21</td><td rowspan="2">4.70</td><td>16.64</td><td>6.34</td><td>4.06</td><td>0.053</td></tr><tr><td/><td>PCB</td><td>17.24</td><td>6.44</td><td/><td/></tr><tr><td>&#x02003;VFL</td><td>DCS</td><td rowspan="2">17.55</td><td rowspan="2">9.58</td><td>18.12</td><td>8.23</td><td>1.06</td><td>0.31</td></tr><tr><td/><td>PCB</td><td>18.48</td><td>8.20</td><td/><td/></tr><tr><td>&#x02003;TOL</td><td>DCS</td><td rowspan="2">14.73</td><td rowspan="2">5.57</td><td>15.70</td><td>5.62</td><td>0.13</td><td>0.72</td></tr><tr><td/><td>PCB</td><td>16.00</td><td>4.33</td><td/><td/></tr><tr><td colspan="8">EQS</td></tr><tr><td>&#x02003;intra</td><td>DCS</td><td rowspan="2">39.29</td><td rowspan="2">14.40</td><td>41.04</td><td>18.23</td><td>0.08</td><td>0.78</td></tr><tr><td/><td>PCB</td><td>38.75</td><td>15.28</td><td/><td/></tr><tr><td>&#x02003;inter</td><td>DCS</td><td rowspan="2">38.18</td><td rowspan="2">14.54</td><td>38.25</td><td>15.77</td><td>1.53</td><td>0.23</td></tr><tr><td/><td>PCB</td><td>38.75</td><td>15.28</td><td/><td/></tr><tr><td>&#x02003;situa</td><td>DCS</td><td rowspan="2">30.79</td><td rowspan="2">16.89</td><td>33.46</td><td>18.66</td><td>0.00</td><td>0.99</td></tr><tr><td/><td>PCB</td><td>32.36</td><td>17.20</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>BACS</italic> Brief Assessment of Cognition in Schizophrenia, <italic>VM</italic> verbal memory, <italic>DS</italic> digit sequencing task, <italic>TM</italic> token motor task, <italic>SC</italic> symbolic coding, <italic>VFC</italic> verbal fluency of category, <italic>VFL</italic> verbal fluency of letter, <italic>TOL</italic> tower of London, <italic>EQS</italic> Emotional Intelligence Scale, <italic>intra</italic> intrapersonal domain, <italic>inter</italic> interpersonal domain, situa, situational domain; &#x02018;Baseline&#x02019; indicates Week 0 both for the first and second phase</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec18"><title>Differences of DCS-effect by onset age</title><p id="Par61">There was no overall effect of onset age on PANSS subscales (F(3, 31)&#x000a0;=&#x000a0;2.20, <italic>p</italic>&#x000a0;=&#x000a0;0.11). However, there was a significant effect of onset age on negative symptoms (F(1, 33)&#x000a0;=&#x000a0;6.17, <italic>p</italic>&#x000a0;=&#x000a0;0.02) (Table <xref rid="Tab4" ref-type="table">4</xref>). In the non-EOS group, the scores for both DCS and PCB declined as time proceeded and almost no difference was noted in the DCS-effect at 6&#x000a0;W (the score of DCS phase subtracted by the one of PCB phase was &#x02212;0.07). In the EOS group, the score for PCB declined as time proceeded whereas the one for DCS demonstrated less decline or even an increase, resulting in the positive value for the DCS-effect at 6&#x000a0;W (the score of DCS phase subtracted by the one of PCB phase was +2.2) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). No significant difference was noted in the overall effect between EOS and non-EOS on SANS, BACS, or EQS, and no significant difference was noted in any subscale. None of the psychometrics ratings of one patient with late onset were outliers.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Differences of DCS-effect by onset age</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>DCS-effect</th><th>SD</th><th>F value</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>PANSS</td><td/><td/><td/><td>2.20</td><td>0.11</td></tr><tr><td>&#x02003;Positive</td><td>EOS</td><td>0.83</td><td>1.83</td><td>1.54</td><td>0.22</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.07</td><td>1.39</td><td/><td/></tr><tr><td>&#x02003;Negative</td><td>EOS</td><td>2.17</td><td>2.79</td><td>6.17</td><td>
<bold>0.02</bold>
</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.07</td><td>1.76</td><td/><td/></tr><tr><td>&#x02003;General</td><td>EOS</td><td>1.33</td><td>3.50</td><td>1.72</td><td>0.20</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.60</td><td>3.07</td><td/><td/></tr><tr><td>SANS</td><td/><td/><td/><td>1.11</td><td>0.38</td></tr><tr><td>&#x02003;I</td><td>EOS</td><td>1.50</td><td>2.74</td><td>2.02</td><td>0.16</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.40</td><td>2.49</td><td/><td/></tr><tr><td>&#x02003;II</td><td>EOS</td><td>0.50</td><td>0.84</td><td>0.57</td><td>0.46</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.23</td><td>1.72</td><td/><td/></tr><tr><td>&#x02003;III</td><td>EOS</td><td>&#x02212;0.50</td><td>1.52</td><td>0.20</td><td>0.66</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.10</td><td>1.60</td><td/><td/></tr><tr><td>&#x02003;IV</td><td>EOS</td><td>0.17</td><td>1.33</td><td>0.54</td><td>0.47</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.50</td><td>1.81</td><td/><td/></tr><tr><td>&#x02003;V</td><td>EOS</td><td>0.67</td><td>1.51</td><td>0.70</td><td>0.41</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.23</td><td>1.76</td><td/><td/></tr><tr><td>Summary</td><td>EOS</td><td>0.83</td><td>1.83</td><td>1.95</td><td>0.17</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.30</td><td>1.51</td><td/><td/></tr><tr><td>Total</td><td>EOS</td><td>2.33</td><td>5.82</td><td>0.92</td><td>0.34</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;1.47</td><td>7.22</td><td/><td/></tr><tr><td>BACS</td><td/><td/><td/><td>0.85</td><td>0.56</td></tr><tr><td>&#x02003;VM</td><td>EOS</td><td>&#x02212;2.83</td><td>9.28</td><td>1.64</td><td>0.21</td></tr><tr><td/><td>non-EOS</td><td>0.68</td><td>5.12</td><td/><td/></tr><tr><td>&#x02003;DS</td><td>EOS</td><td>&#x02212;0.17</td><td>2.32</td><td>0.19</td><td>0.66</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.68</td><td>3.42</td><td/><td/></tr><tr><td>&#x02003;TM</td><td>EOS</td><td>0.67</td><td>5.75</td><td>0.47</td><td>0.50</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;3.96</td><td>14.86</td><td/><td/></tr><tr><td>&#x02003;SC</td><td>EOS</td><td>&#x02212;1.67</td><td>6.12</td><td>0.01</td><td>0.94</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;1.39</td><td>7.02</td><td/><td/></tr><tr><td>&#x02003;VFC</td><td>EOS</td><td>&#x02212;3.17</td><td>3.54</td><td>2.69</td><td>0.11</td></tr><tr><td/><td>non-EOS</td><td>0.04</td><td>3.70</td><td/><td/></tr><tr><td>&#x02003;VFL</td><td>EOS</td><td>0.67</td><td>3.14</td><td>0.51</td><td>0.48</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.61</td><td>5.79</td><td/><td/></tr><tr><td>&#x02003;TOL</td><td>EOS</td><td>0.00</td><td>3.69</td><td>0.02</td><td>0.90</td></tr><tr><td/><td>non-EOS</td><td>&#x02212;0.29</td><td>3.75</td><td/><td/></tr><tr><td>EQS</td><td/><td/><td/><td>1.18</td><td>0.34</td></tr><tr><td>&#x02003;intra</td><td>EOS</td><td>&#x02212;0.60</td><td>12.82</td><td>0.86</td><td>0.36</td></tr><tr><td/><td>non-EOS</td><td>2.58</td><td>6.10</td><td/><td/></tr><tr><td>&#x02003;inter</td><td>EOS</td><td>&#x02212;2.40</td><td>9.21</td><td>0.65</td><td>0.43</td></tr><tr><td/><td>non-EOS</td><td>0.17</td><td>8.69</td><td/><td/></tr><tr><td>&#x02003;situa</td><td>EOS</td><td>3.00</td><td>6.12</td><td>0.53</td><td>0.47</td></tr><tr><td/><td>non-EOS</td><td>0.79</td><td>6.06</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>PANSS</italic> Positive and Negative Syndrome Scale, <italic>SANS</italic> Scale for the Assessment of Negative Symptoms, <italic>BACS</italic> Brief Assessment of Cognition in Schizophrenia, <italic>VM</italic> verbal memory, <italic>DS</italic> digit sequencing task, <italic>TM</italic> token motor task, <italic>SC</italic> symbolic coding, <italic>VFC</italic> verbal fluency of category, <italic>VFL</italic> verbal fluency of letter, <italic>TOL</italic> tower of London, <italic>EQS</italic> Emotional Intelligence Scale, <italic>intra</italic> intrapersonal domain, <italic>inter</italic> interpersonal domain, <italic>situa</italic> situational domain, <italic>SD</italic> standard deviation; DCS-effect, scores at DCS phase extracted by those at PCB phase</p></table-wrap-foot></table-wrap>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Changes in the scores of PANSS negative symptom</p><p>PANSS, Positive and Negative Syndrome Scale; DCS-effect was defined by scores at DCS phase subtracted by those at PCB phase. In the non-EOS group, the scores for both DCS and PCB declined as time proceeded and almost no difference (&#x02212;0.07) was noted in the DCS-effect at 6&#x000a0;W. In the EOS group, the score for PCB declined as time proceeded whereas the one for DCS demonstrated less decline or even an increase, resulting in the positive value (+2.2) for the DCS-effect at 6&#x000a0;W</p></caption><graphic xlink:href="12888_2017_1410_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec19"><title>MR diffusion tensor imaging</title><p id="Par62">Data could be collected from 21 of the 36 patients who completed the study. These participants were those who agreed and traveled to TMDU for the MRI scan, comprising the 3 EOS and 18 non-EOS patients. Regarding the subscales of PANSS, SANS, BACS, and EQS, the correlation between the FA value of each brain region and DCS-effect was investigated (Table <xref rid="Tab5" ref-type="table">5</xref>). The significant correlations (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) were demonstrated in PANSS-G, SANS-IV, BACS-TM, and BACS-TOL.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Correlation between the FA value of each brain region and DCS-effect</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="3">PANSS</th><th colspan="7">SANS</th><th colspan="7">BACS</th><th colspan="3">EQS</th></tr><tr><th colspan="2"/><th>P</th><th>N</th><th>G</th><th>I</th><th>II</th><th>III</th><th>IV</th><th>V</th><th>Sumarry</th><th>Total</th><th>VM</th><th>DS</th><th>TM</th><th>SC</th><th>VFC</th><th>FVL</th><th>TOL</th><th>intra</th><th>inter</th><th>situa</th></tr></thead><tbody><tr><td rowspan="3">middle cerebellar peduncle</td><td>r</td><td>&#x02212;.014</td><td>&#x02212;.242</td><td>&#x02212;.023</td><td>.071</td><td>.139</td><td>&#x02212;.120</td><td>&#x02212;.061</td><td>&#x02212;.304</td><td>&#x02212;.310</td><td>&#x02212;.104</td><td>.070</td><td>.344</td><td>.281</td><td>.042</td><td>&#x02212;.243</td><td>&#x02212;.034</td><td>.012</td><td>.081</td><td>&#x02212;.414</td><td>&#x02212;.375</td></tr><tr><td>p</td><td>.952</td><td>.290</td><td>.922</td><td>.759</td><td>.549</td><td>.605</td><td>.793</td><td>.180</td><td>.171</td><td>.654</td><td>.769</td><td>.137</td><td>.230</td><td>.859</td><td>.302</td><td>.888</td><td>.960</td><td>.782</td><td>.141</td><td>.187</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">pontine crossing tract</td><td>r</td><td>.291</td><td>
<bold>&#x02212;.539</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.140</td><td>&#x02212;.187</td><td>.173</td><td>.051</td><td>&#x02212;.373</td><td>&#x02212;.028</td><td>&#x02212;.302</td><td>&#x02212;.134</td><td>&#x02212;.070</td><td>.365</td><td>.392</td><td>&#x02212;.080</td><td>.079</td><td>.171</td><td>.180</td><td>.162</td><td>&#x02212;.107</td><td>&#x02212;.269</td></tr><tr><td>p</td><td>.201</td><td>
<bold>.012</bold>
</td><td>.545</td><td>.417</td><td>.453</td><td>.827</td><td>.096</td><td>.906</td><td>.184</td><td>.563</td><td>.768</td><td>.114</td><td>.087</td><td>.738</td><td>.740</td><td>.472</td><td>.447</td><td>.581</td><td>.716</td><td>.352</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">genu of corpus callosum</td><td>r</td><td>.189</td><td>.121</td><td>.303</td><td>&#x02212;.078</td><td>.148</td><td>.292</td><td>.123</td><td>.095</td><td>.072</td><td>.169</td><td>&#x02212;.443</td><td>&#x02212;.076</td><td>.228</td><td>&#x02212;.095</td><td>&#x02212;.214</td><td>&#x02212;.007</td><td>
<bold>.585</bold>
<sup><bold>**</bold></sup>
</td><td>.066</td><td>.380</td><td>.253</td></tr><tr><td>p</td><td>.412</td><td>.602</td><td>.182</td><td>.735</td><td>.522</td><td>.200</td><td>.596</td><td>.682</td><td>.756</td><td>.464</td><td>.050</td><td>.751</td><td>.334</td><td>.689</td><td>.365</td><td>.977</td><td>
<bold>.007</bold>
</td><td>.822</td><td>.181</td><td>.383</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">body of corpus callosum</td><td>r</td><td>.386</td><td>&#x02212;.082</td><td>&#x02212;.042</td><td>&#x02212;.013</td><td>.358</td><td>.156</td><td>&#x02212;.110</td><td>.170</td><td>.087</td><td>.161</td><td>&#x02212;.102</td><td>.182</td><td>.283</td><td>.140</td><td>&#x02212;.230</td><td>&#x02212;.011</td><td>
<bold>.460</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.073</td><td>.429</td><td>.108</td></tr><tr><td>p</td><td>.084</td><td>.723</td><td>.858</td><td>.957</td><td>.111</td><td>.499</td><td>.636</td><td>.462</td><td>.708</td><td>.485</td><td>.670</td><td>.442</td><td>.226</td><td>.557</td><td>.329</td><td>.962</td><td>
<bold>.041</bold>
</td><td>.804</td><td>.126</td><td>.714</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">splenium of corpus callosum</td><td>r</td><td>
<bold>&#x02212;.444</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.432</td><td>
<bold>&#x02212;.574</bold>
<sup><bold>**</bold></sup>
</td><td>
<bold>&#x02212;.439</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.115</td><td>.212</td><td>&#x02212;.404</td><td>&#x02212;.353</td><td>&#x02212;.347</td><td>&#x02212;.378</td><td>.092</td><td>.318</td><td>&#x02212;.235</td><td>&#x02212;.015</td><td>.121</td><td>&#x02212;.136</td><td>&#x02212;.202</td><td>&#x02212;.325</td><td>&#x02212;.182</td><td>&#x02212;.163</td></tr><tr><td>p</td><td>
<bold>.044</bold>
</td><td>.050</td><td>
<bold>.007</bold>
</td><td>
<bold>.047</bold>
</td><td>.621</td><td>.356</td><td>.069</td><td>.117</td><td>.123</td><td>.091</td><td>.699</td><td>.171</td><td>.318</td><td>.949</td><td>.611</td><td>.568</td><td>.393</td><td>.257</td><td>.534</td><td>.577</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">fornix</td><td>r</td><td>.334</td><td>.052</td><td>.146</td><td>&#x02212;.089</td><td>.319</td><td>.180</td><td>&#x02212;.120</td><td>.082</td><td>.082</td><td>.096</td><td>&#x02212;.095</td><td>.200</td><td>
<bold>.517</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.067</td><td>.017</td><td>&#x02212;.062</td><td>
<bold>.519</bold>
<sup><bold>*</bold></sup>
</td><td>.090</td><td>.471</td><td>.412</td></tr><tr><td>p</td><td>.139</td><td>.823</td><td>.529</td><td>.703</td><td>.158</td><td>.435</td><td>.605</td><td>.725</td><td>.725</td><td>.680</td><td>.689</td><td>.397</td><td>
<bold>.020</bold>
</td><td>.780</td><td>.942</td><td>.797</td><td>
<bold>.019</bold>
</td><td>.759</td><td>.089</td><td>.143</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">corticospinal tract R</td><td>r</td><td>.300</td><td>&#x02212;.120</td><td>.023</td><td>&#x02212;.096</td><td>.066</td><td>&#x02212;.167</td><td>.063</td><td>&#x02212;.132</td><td>&#x02212;.141</td><td>&#x02212;.099</td><td>.304</td><td>.196</td><td>.021</td><td>.197</td><td>.189</td><td>
<bold>.530</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.127</td><td>.173</td><td>&#x02212;.431</td><td>&#x02212;.038</td></tr><tr><td>p</td><td>.187</td><td>.605</td><td>.923</td><td>.678</td><td>.775</td><td>.468</td><td>.787</td><td>.567</td><td>.543</td><td>.669</td><td>.193</td><td>.408</td><td>.928</td><td>.406</td><td>.425</td><td>
<bold>.016</bold>
</td><td>.593</td><td>.555</td><td>.124</td><td>.898</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">corticospinal tract L</td><td>r</td><td>.129</td><td>&#x02212;.023</td><td>&#x02212;.013</td><td>&#x02212;.055</td><td>.107</td><td>&#x02212;.313</td><td>.085</td><td>&#x02212;.159</td><td>&#x02212;.084</td><td>&#x02212;.121</td><td>.435</td><td>.200</td><td>&#x02212;.045</td><td>.258</td><td>.219</td><td>
<bold>.471</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.227</td><td>.161</td><td>&#x02212;.278</td><td>&#x02212;.053</td></tr><tr><td>p</td><td>.576</td><td>.920</td><td>.955</td><td>.811</td><td>.645</td><td>.167</td><td>.713</td><td>.492</td><td>.716</td><td>.601</td><td>.056</td><td>.397</td><td>.851</td><td>.272</td><td>.353</td><td>
<bold>.036</bold>
</td><td>.336</td><td>.582</td><td>.335</td><td>.858</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">medial lemniscus R</td><td>r</td><td>.255</td><td>.193</td><td>&#x02212;.011</td><td>&#x02212;.120</td><td>.136</td><td>.193</td><td>.188</td><td>&#x02212;.114</td><td>&#x02212;.022</td><td>.064</td><td>.141</td><td>&#x02212;.082</td><td>.249</td><td>.232</td><td>&#x02212;.034</td><td>.118</td><td>.342</td><td>&#x02212;.287</td><td>&#x02212;.058</td><td>.131</td></tr><tr><td>p</td><td>.265</td><td>.402</td><td>.961</td><td>.605</td><td>.557</td><td>.403</td><td>.414</td><td>.622</td><td>.925</td><td>.782</td><td>.553</td><td>.732</td><td>.289</td><td>.326</td><td>.885</td><td>.621</td><td>.141</td><td>.319</td><td>.844</td><td>.654</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">medial lemniscus L</td><td>r</td><td>.236</td><td>.023</td><td>&#x02212;.188</td><td>&#x02212;.206</td><td>.113</td><td>.066</td><td>.067</td><td>&#x02212;.154</td><td>&#x02212;.078</td><td>&#x02212;.064</td><td>.189</td><td>.094</td><td>.219</td><td>.287</td><td>.031</td><td>.163</td><td>.308</td><td>&#x02212;.270</td><td>.058</td><td>.104</td></tr><tr><td>p</td><td>.303</td><td>.920</td><td>.415</td><td>.369</td><td>.625</td><td>.777</td><td>.774</td><td>.505</td><td>.736</td><td>.784</td><td>.425</td><td>.693</td><td>.354</td><td>.220</td><td>.896</td><td>.493</td><td>.186</td><td>.350</td><td>.845</td><td>.723</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">inferior cerebellar peduncle R</td><td>r</td><td>.367</td><td>&#x02212;.094</td><td>&#x02212;.181</td><td>.020</td><td>&#x02212;.065</td><td>.324</td><td>&#x02212;.040</td><td>&#x02212;.043</td><td>&#x02212;.082</td><td>.063</td><td>&#x02212;.179</td><td>.040</td><td>.187</td><td>&#x02212;.277</td><td>&#x02212;.111</td><td>.131</td><td>.397</td><td>&#x02212;.241</td><td>&#x02212;.105</td><td>.008</td></tr><tr><td>p</td><td>.102</td><td>.685</td><td>.433</td><td>.932</td><td>.780</td><td>.152</td><td>.863</td><td>.854</td><td>.723</td><td>.787</td><td>.451</td><td>.868</td><td>.430</td><td>.238</td><td>.642</td><td>.583</td><td>.083</td><td>.406</td><td>.721</td><td>.977</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">inferior cerebellar peduncle L</td><td>r</td><td>.396</td><td>&#x02212;.133</td><td>&#x02212;.212</td><td>.025</td><td>.121</td><td>.268</td><td>&#x02212;.061</td><td>.118</td><td>.017</td><td>.146</td><td>&#x02212;.105</td><td>.062</td><td>.252</td><td>&#x02212;.078</td><td>.022</td><td>.268</td><td>.354</td><td>&#x02212;.146</td><td>.126</td><td>.018</td></tr><tr><td>p</td><td>.076</td><td>.566</td><td>.357</td><td>.915</td><td>.601</td><td>.240</td><td>.791</td><td>.610</td><td>.942</td><td>.528</td><td>.660</td><td>.796</td><td>.284</td><td>.745</td><td>.926</td><td>.254</td><td>.126</td><td>.618</td><td>.667</td><td>.952</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior cerebellar peduncle R</td><td>r</td><td>&#x02212;.203</td><td>&#x02212;.091</td><td>&#x02212;.349</td><td>&#x02212;.012</td><td>&#x02212;.234</td><td>&#x02212;.186</td><td>&#x02212;.212</td><td>&#x02212;.233</td><td>&#x02212;.225</td><td>&#x02212;.269</td><td>.296</td><td>.217</td><td>.015</td><td>.330</td><td>.083</td><td>.179</td><td>.105</td><td>&#x02212;.156</td><td>&#x02212;.071</td><td>&#x02212;.152</td></tr><tr><td>p</td><td>.376</td><td>.694</td><td>.121</td><td>.959</td><td>.307</td><td>.420</td><td>.357</td><td>.310</td><td>.327</td><td>.238</td><td>.204</td><td>.359</td><td>.949</td><td>.156</td><td>.729</td><td>.449</td><td>.660</td><td>.594</td><td>.808</td><td>.605</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior cerebellar peduncle L</td><td>r</td><td>&#x02212;.186</td><td>&#x02212;.229</td><td>
<bold>&#x02212;.484</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.006</td><td>&#x02212;.361</td><td>&#x02212;.247</td><td>&#x02212;.263</td><td>&#x02212;.313</td><td>&#x02212;.379</td><td>&#x02212;.362</td><td>.153</td><td>.245</td><td>.118</td><td>.104</td><td>.084</td><td>.174</td><td>.166</td><td>&#x02212;.253</td><td>&#x02212;.153</td><td>&#x02212;.161</td></tr><tr><td>p</td><td>.419</td><td>.319</td><td>
<bold>.026</bold>
</td><td>.978</td><td>.108</td><td>.280</td><td>.249</td><td>.167</td><td>.090</td><td>.107</td><td>.519</td><td>.298</td><td>.620</td><td>.662</td><td>.726</td><td>.462</td><td>.483</td><td>.384</td><td>.601</td><td>.582</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">cereberal peduncle R</td><td>r</td><td>.075</td><td>&#x02212;.164</td><td>&#x02212;.245</td><td>.125</td><td>&#x02212;.055</td><td>.028</td><td>&#x02212;.221</td><td>&#x02212;.085</td><td>&#x02212;.169</td><td>&#x02212;.057</td><td>&#x02212;.089</td><td>.178</td><td>
<bold>.465</bold>
<sup><bold>*</bold></sup>
</td><td>.196</td><td>.082</td><td>&#x02212;.050</td><td>.049</td><td>.023</td><td>.043</td><td>.479</td></tr><tr><td>p</td><td>.748</td><td>.477</td><td>.285</td><td>.590</td><td>.812</td><td>.905</td><td>.336</td><td>.716</td><td>.465</td><td>.807</td><td>.708</td><td>.452</td><td>
<bold>.039</bold>
</td><td>.406</td><td>.731</td><td>.833</td><td>.838</td><td>.938</td><td>.885</td><td>.083</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">cereberal peduncle L</td><td>r</td><td>&#x02212;.307</td><td>&#x02212;.053</td><td>&#x02212;.179</td><td>&#x02212;.003</td><td>&#x02212;.180</td><td>.260</td><td>&#x02212;.189</td><td>&#x02212;.145</td><td>&#x02212;.131</td><td>&#x02212;.077</td><td>&#x02212;.358</td><td>.074</td><td>&#x02212;.013</td><td>&#x02212;.048</td><td>&#x02212;.016</td><td>&#x02212;.129</td><td>.324</td><td>&#x02212;.022</td><td>.147</td><td>.257</td></tr><tr><td>p</td><td>.175</td><td>.818</td><td>.438</td><td>.989</td><td>.435</td><td>.255</td><td>.413</td><td>.532</td><td>.572</td><td>.741</td><td>.121</td><td>.758</td><td>.956</td><td>.842</td><td>.946</td><td>.587</td><td>.164</td><td>.941</td><td>.617</td><td>.375</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">anterior limb of internal capsule R</td><td>r</td><td>.189</td><td>.220</td><td>.315</td><td>.101</td><td>.054</td><td>.353</td><td>.202</td><td>.028</td><td>.157</td><td>.231</td><td>.015</td><td>&#x02212;.225</td><td>.295</td><td>.325</td><td>.371</td><td>&#x02212;.163</td><td>.223</td><td>&#x02212;.275</td><td>.085</td><td>.354</td></tr><tr><td>p</td><td>.412</td><td>.339</td><td>.165</td><td>.663</td><td>.815</td><td>.116</td><td>.380</td><td>.903</td><td>.497</td><td>.314</td><td>.950</td><td>.341</td><td>.207</td><td>.162</td><td>.107</td><td>.493</td><td>.344</td><td>.342</td><td>.772</td><td>.214</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">anterior limb of internal capsule L</td><td>r</td><td>.033</td><td>.086</td><td>.262</td><td>&#x02212;.136</td><td>&#x02212;.143</td><td>.310</td><td>.151</td><td>.002</td><td>&#x02212;.057</td><td>.055</td><td>&#x02212;.425</td><td>&#x02212;.239</td><td>.083</td><td>.050</td><td>.014</td><td>&#x02212;.195</td><td>
<bold>.463</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.118</td><td>.070</td><td>.216</td></tr><tr><td>p</td><td>.886</td><td>.710</td><td>.252</td><td>.558</td><td>.537</td><td>.171</td><td>.514</td><td>.993</td><td>.807</td><td>.813</td><td>.062</td><td>.311</td><td>.728</td><td>.834</td><td>.952</td><td>.411</td><td>
<bold>.040</bold>
</td><td>.689</td><td>.813</td><td>.459</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">posterior limb of internal capsule R</td><td>r</td><td>&#x02212;.413</td><td>&#x02212;.326</td><td>&#x02212;.369</td><td>&#x02212;.323</td><td>&#x02212;.113</td><td>.144</td><td>&#x02212;.402</td><td>&#x02212;.395</td><td>&#x02212;.303</td><td>&#x02212;.370</td><td>&#x02212;.018</td><td>.198</td><td>&#x02212;.003</td><td>.258</td><td>.356</td><td>&#x02212;.218</td><td>&#x02212;.422</td><td>.015</td><td>&#x02212;.087</td><td>.287</td></tr><tr><td>p</td><td>.063</td><td>.149</td><td>.100</td><td>.154</td><td>.624</td><td>.533</td><td>.071</td><td>.076</td><td>.181</td><td>.099</td><td>.940</td><td>.403</td><td>.989</td><td>.272</td><td>.123</td><td>.356</td><td>.064</td><td>.960</td><td>.767</td><td>.320</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">posterior limb of internal capsule L</td><td>r</td><td>&#x02212;.383</td><td>&#x02212;.363</td><td>&#x02212;.251</td><td>&#x02212;.288</td><td>&#x02212;.180</td><td>.153</td><td>&#x02212;.177</td><td>&#x02212;.394</td><td>&#x02212;.239</td><td>&#x02212;.302</td><td>.083</td><td>.235</td><td>
<bold>&#x02212;.477</bold>
<sup><bold>*</bold></sup>
</td><td>.112</td><td>.193</td><td>&#x02212;.098</td><td>&#x02212;.433</td><td>&#x02212;.223</td><td>&#x02212;.216</td><td>&#x02212;.141</td></tr><tr><td>p</td><td>.087</td><td>.106</td><td>.272</td><td>.205</td><td>.436</td><td>.507</td><td>.444</td><td>.077</td><td>.297</td><td>.183</td><td>.728</td><td>.318</td><td>
<bold>.033</bold>
</td><td>.639</td><td>.416</td><td>.682</td><td>.057</td><td>.444</td><td>.459</td><td>.630</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">retrolenticular part of internal capsule R</td><td>r</td><td>
<bold>&#x02212;.465</bold>
<sup><bold>*</bold></sup>
</td><td>.224</td><td>&#x02212;.008</td><td>&#x02212;.293</td><td>&#x02212;.353</td><td>&#x02212;.118</td><td>.064</td><td>&#x02212;.377</td><td>&#x02212;.270</td><td>&#x02212;.352</td><td>&#x02212;.153</td><td>&#x02212;.380</td><td>&#x02212;.105</td><td>.255</td><td>&#x02212;.033</td><td>&#x02212;.307</td><td>&#x02212;.256</td><td>.079</td><td>&#x02212;.118</td><td>
<bold>.604</bold>
<sup><bold>*</bold></sup>
</td></tr><tr><td>p</td><td>
<bold>.034</bold>
</td><td>.330</td><td>.972</td><td>.197</td><td>.116</td><td>.609</td><td>.783</td><td>.092</td><td>.236</td><td>.118</td><td>.519</td><td>.098</td><td>.660</td><td>.277</td><td>.889</td><td>.188</td><td>.277</td><td>.789</td><td>.687</td><td>
<bold>.022</bold>
</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">retrolenticular part of internal capsule L</td><td>r</td><td>&#x02212;.249</td><td>&#x02212;.021</td><td>.030</td><td>&#x02212;.017</td><td>.052</td><td>.167</td><td>.044</td><td>&#x02212;.202</td><td>&#x02212;.090</td><td>&#x02212;.002</td><td>&#x02212;.057</td><td>&#x02212;.056</td><td>&#x02212;.072</td><td>.270</td><td>&#x02212;.039</td><td>.105</td><td>&#x02212;.319</td><td>.418</td><td>&#x02212;.095</td><td>.329</td></tr><tr><td>p</td><td>.276</td><td>.927</td><td>.898</td><td>.942</td><td>.824</td><td>.469</td><td>.850</td><td>.380</td><td>.698</td><td>.993</td><td>.811</td><td>.816</td><td>.763</td><td>.249</td><td>.871</td><td>.659</td><td>.171</td><td>.137</td><td>.746</td><td>.251</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">anterior corona radiata R</td><td>r</td><td>.246</td><td>.285</td><td>
<bold>.440</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.248</td><td>.045</td><td>.213</td><td>.386</td><td>&#x02212;.088</td><td>&#x02212;.036</td><td>.070</td><td>.082</td><td>&#x02212;.189</td><td>.170</td><td>&#x02212;.058</td><td>.114</td><td>&#x02212;.181</td><td>.353</td><td>&#x02212;.256</td><td>&#x02212;.156</td><td>.218</td></tr><tr><td>p</td><td>.282</td><td>.210</td><td>
<bold>.046</bold>
</td><td>.279</td><td>.846</td><td>.354</td><td>.084</td><td>.704</td><td>.876</td><td>.764</td><td>.731</td><td>.424</td><td>.474</td><td>.807</td><td>.631</td><td>.444</td><td>.126</td><td>.378</td><td>.594</td><td>.454</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">anterior corona radiata L</td><td>r</td><td>.052</td><td>.081</td><td>.197</td><td>&#x02212;.421</td><td>.152</td><td>.257</td><td>.204</td><td>&#x02212;.120</td><td>&#x02212;.079</td><td>&#x02212;.021</td><td>&#x02212;.003</td><td>&#x02212;.012</td><td>.186</td><td>&#x02212;.207</td><td>.157</td><td>&#x02212;.176</td><td>.129</td><td>&#x02212;.117</td><td>&#x02212;.045</td><td>.286</td></tr><tr><td>p</td><td>.824</td><td>.727</td><td>.391</td><td>.057</td><td>.510</td><td>.260</td><td>.375</td><td>.605</td><td>.734</td><td>.928</td><td>.991</td><td>.959</td><td>.432</td><td>.381</td><td>.508</td><td>.457</td><td>.586</td><td>.690</td><td>.879</td><td>.322</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior corona radiata R</td><td>r</td><td>&#x02212;.272</td><td>.141</td><td>&#x02212;.059</td><td>.148</td><td>.045</td><td>.364</td><td>.053</td><td>&#x02212;.049</td><td>.144</td><td>.176</td><td>.112</td><td>&#x02212;.141</td><td>&#x02212;.264</td><td>.243</td><td>.051</td><td>&#x02212;.290</td><td>.042</td><td>&#x02212;.385</td><td>&#x02212;.044</td><td>&#x02212;.075</td></tr><tr><td>p</td><td>.233</td><td>.541</td><td>.798</td><td>.522</td><td>.846</td><td>.105</td><td>.820</td><td>.832</td><td>.532</td><td>.445</td><td>.640</td><td>.554</td><td>.262</td><td>.302</td><td>.831</td><td>.215</td><td>.861</td><td>.174</td><td>.880</td><td>.799</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior corona radiata L</td><td>r</td><td>&#x02212;.100</td><td>.196</td><td>.007</td><td>&#x02212;.026</td><td>.102</td><td>.398</td><td>.295</td><td>.055</td><td>.290</td><td>.247</td><td>.181</td><td>&#x02212;.170</td><td>&#x02212;.401</td><td>.316</td><td>&#x02212;.027</td><td>&#x02212;.066</td><td>&#x02212;.021</td><td>
<bold>&#x02212;.614</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.011</td><td>&#x02212;.133</td></tr><tr><td>p</td><td>.668</td><td>.395</td><td>.974</td><td>.910</td><td>.661</td><td>.074</td><td>.194</td><td>.812</td><td>.202</td><td>.280</td><td>.445</td><td>.473</td><td>.080</td><td>.175</td><td>.912</td><td>.782</td><td>.932</td><td>
<bold>.019</bold>
</td><td>.971</td><td>.650</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">posterior corona radiata R</td><td>r</td><td>&#x02212;.374</td><td>&#x02212;.058</td><td>&#x02212;.111</td><td>&#x02212;.073</td><td>.178</td><td>.169</td><td>.067</td><td>&#x02212;.137</td><td>.054</td><td>.040</td><td>&#x02212;.241</td><td>&#x02212;.186</td><td>&#x02212;.292</td><td>.110</td><td>&#x02212;.166</td><td>&#x02212;.244</td><td>
<bold>&#x02212;.529</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.120</td><td>&#x02212;.195</td><td>&#x02212;.036</td></tr><tr><td>p</td><td>.095</td><td>.804</td><td>.633</td><td>.754</td><td>.439</td><td>.463</td><td>.772</td><td>.552</td><td>.816</td><td>.862</td><td>.306</td><td>.433</td><td>.211</td><td>.645</td><td>.485</td><td>.300</td><td>
<bold>.017</bold>
</td><td>.683</td><td>.505</td><td>.904</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>
<bold>20</bold>
</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">posterior corona radiata L</td><td>r</td><td>&#x02212;.154</td><td>.013</td><td>.021</td><td>&#x02212;.006</td><td>.136</td><td>.178</td><td>.346</td><td>&#x02212;.043</td><td>.174</td><td>.176</td><td>&#x02212;.198</td><td>&#x02212;.228</td><td>&#x02212;.357</td><td>.043</td><td>&#x02212;.190</td><td>&#x02212;.099</td><td>&#x02212;.312</td><td>
<bold>&#x02212;.549</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.274</td><td>&#x02212;.481</td></tr><tr><td>p</td><td>.505</td><td>.955</td><td>.927</td><td>.980</td><td>.557</td><td>.440</td><td>.125</td><td>.853</td><td>.451</td><td>.445</td><td>.402</td><td>.333</td><td>.123</td><td>.858</td><td>.422</td><td>.678</td><td>.180</td><td>
<bold>.042</bold>
</td><td>.343</td><td>.082</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">posterior thalamic radiation R</td><td>r</td><td>.238</td><td>.026</td><td>.223</td><td>&#x02212;.341</td><td>.079</td><td>&#x02212;.013</td><td>.198</td><td>&#x02212;.265</td><td>&#x02212;.259</td><td>&#x02212;.147</td><td>.019</td><td>.010</td><td>.268</td><td>.137</td><td>&#x02212;.202</td><td>&#x02212;.118</td><td>&#x02212;.135</td><td>.150</td><td>&#x02212;.315</td><td>
<bold>.553</bold>
<sup><bold>*</bold></sup>
</td></tr><tr><td>p</td><td>.298</td><td>.910</td><td>.331</td><td>.130</td><td>.733</td><td>.955</td><td>.389</td><td>.245</td><td>.257</td><td>.525</td><td>.936</td><td>.965</td><td>.253</td><td>.565</td><td>.393</td><td>.619</td><td>.570</td><td>.609</td><td>.272</td><td>
<bold>.040</bold>
</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">posterior thalamic radiation L</td><td>r</td><td>.183</td><td>
<bold>.443</bold>
<sup><bold>*</bold></sup>
</td><td>
<bold>.571</bold>
<sup><bold>**</bold></sup>
</td><td>&#x02212;.010</td><td>&#x02212;.005</td><td>.147</td><td>
<bold>.598</bold>
<sup><bold>**</bold></sup>
</td><td>&#x02212;.008</td><td>.111</td><td>.219</td><td>&#x02212;.195</td><td>&#x02212;.389</td><td>.016</td><td>.107</td><td>&#x02212;.352</td><td>&#x02212;.113</td><td>.275</td><td>.039</td><td>&#x02212;.094</td><td>.353</td></tr><tr><td>p</td><td>.427</td><td>
<bold>.044</bold>
</td><td>
<bold>.007</bold>
</td><td>.965</td><td>.983</td><td>.526</td><td>
<bold>.004</bold>
</td><td>.972</td><td>.633</td><td>.340</td><td>.409</td><td>.090</td><td>.946</td><td>.653</td><td>.128</td><td>.634</td><td>.241</td><td>.895</td><td>.748</td><td>.216</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">sagittal stratum R</td><td>r</td><td>.190</td><td>&#x02212;.045</td><td>.224</td><td>&#x02212;.240</td><td>.262</td><td>&#x02212;.029</td><td>.186</td><td>&#x02212;.014</td><td>&#x02212;.106</td><td>.019</td><td>&#x02212;.025</td><td>.085</td><td>
<bold>.521</bold>
<sup><bold>*</bold></sup>
</td><td>.254</td><td>.010</td><td>.030</td><td>&#x02212;.048</td><td>.369</td><td>.131</td><td>
<bold>.615</bold>
<sup><bold>*</bold></sup>
</td></tr><tr><td>p</td><td>.410</td><td>.848</td><td>.328</td><td>.295</td><td>.251</td><td>.899</td><td>.419</td><td>.953</td><td>.647</td><td>.934</td><td>.916</td><td>.721</td><td>
<bold>.019</bold>
</td><td>.280</td><td>.967</td><td>.900</td><td>.840</td><td>.194</td><td>.656</td><td>
<bold>.019</bold>
</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">sagittal stratum L</td><td>r</td><td>.191</td><td>.080</td><td>.170</td><td>&#x02212;.301</td><td>.318</td><td>&#x02212;.118</td><td>.224</td><td>&#x02212;.015</td><td>&#x02212;.078</td><td>&#x02212;.005</td><td>.064</td><td>.178</td><td>
<bold>.596</bold>
<sup><bold>**</bold></sup>
</td><td>.061</td><td>&#x02212;.088</td><td>&#x02212;.140</td><td>.285</td><td>.110</td><td>.231</td><td>.355</td></tr><tr><td>p</td><td>.406</td><td>.731</td><td>.462</td><td>.185</td><td>.160</td><td>.610</td><td>.329</td><td>.947</td><td>.736</td><td>.981</td><td>.789</td><td>.453</td><td>
<bold>.006</bold>
</td><td>.799</td><td>.713</td><td>.555</td><td>.224</td><td>.708</td><td>.428</td><td>.212</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">external capsule R</td><td>r</td><td>.300</td><td>.167</td><td>.059</td><td>&#x02212;.027</td><td>.172</td><td>&#x02212;.030</td><td>.076</td><td>.097</td><td>&#x02212;.112</td><td>.082</td><td>&#x02212;.032</td><td>&#x02212;.182</td><td>
<bold>.515</bold>
<sup><bold>*</bold></sup>
</td><td>.253</td><td>&#x02212;.217</td><td>&#x02212;.049</td><td>
<bold>.559</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.019</td><td>.179</td><td>.461</td></tr><tr><td>p</td><td>.186</td><td>.469</td><td>.800</td><td>.908</td><td>.455</td><td>.896</td><td>.743</td><td>.677</td><td>.629</td><td>.723</td><td>.894</td><td>.442</td><td>
<bold>.020</bold>
</td><td>.283</td><td>.357</td><td>.836</td><td>
<bold>.010</bold>
</td><td>.949</td><td>.541</td><td>.097</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">external capsule L</td><td>r</td><td>.179</td><td>.166</td><td>.083</td><td>.095</td><td>.172</td><td>.023</td><td>.041</td><td>.229</td><td>&#x02212;.020</td><td>.181</td><td>&#x02212;.235</td><td>&#x02212;.184</td><td>.386</td><td>.002</td><td>&#x02212;.205</td><td>&#x02212;.180</td><td>
<bold>.702</bold>
<sup><bold>**</bold></sup>
</td><td>&#x02212;.051</td><td>.291</td><td>.228</td></tr><tr><td>p</td><td>.437</td><td>.471</td><td>.721</td><td>.681</td><td>.456</td><td>.923</td><td>.860</td><td>.319</td><td>.932</td><td>.432</td><td>.319</td><td>.437</td><td>.092</td><td>.994</td><td>.386</td><td>.448</td><td>
<bold>.001</bold>
</td><td>.862</td><td>.313</td><td>.432</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">cingulum (cingulate gyrus) R</td><td>r</td><td>
<bold>.455</bold>
<sup><bold>*</bold></sup>
</td><td>.164</td><td>.080</td><td>.116</td><td>&#x02212;.028</td><td>&#x02212;.032</td><td>.227</td><td>.195</td><td>&#x02212;.023</td><td>.166</td><td>&#x02212;.098</td><td>&#x02212;.029</td><td>
<bold>.584</bold>
<sup><bold>**</bold></sup>
</td><td>.078</td><td>&#x02212;.111</td><td>.169</td><td>
<bold>.869</bold>
<sup><bold>**</bold></sup>
</td><td>&#x02212;.041</td><td>.211</td><td>.221</td></tr><tr><td>p</td><td>
<bold>.038</bold>
</td><td>.477</td><td>.732</td><td>.618</td><td>.904</td><td>.891</td><td>.322</td><td>.396</td><td>.922</td><td>.472</td><td>.680</td><td>.903</td><td>
<bold>.007</bold>
</td><td>.743</td><td>.641</td><td>.476</td><td>
<bold>.000</bold>
</td><td>.890</td><td>.470</td><td>.448</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">cingulum (cingulate gyrus) L</td><td>r</td><td>
<bold>.481</bold>
<sup><bold>*</bold></sup>
</td><td>.126</td><td>.307</td><td>.169</td><td>&#x02212;.098</td><td>&#x02212;.037</td><td>.323</td><td>.099</td><td>&#x02212;.148</td><td>.161</td><td>&#x02212;.259</td><td>&#x02212;.216</td><td>
<bold>.575</bold>
<sup><bold>**</bold></sup>
</td><td>.003</td><td>&#x02212;.159</td><td>&#x02212;.159</td><td>
<bold>.664</bold>
<sup><bold>**</bold></sup>
</td><td>&#x02212;.152</td><td>&#x02212;.126</td><td>.185</td></tr><tr><td>p</td><td>
<bold>.027</bold>
</td><td>.587</td><td>.176</td><td>.463</td><td>.672</td><td>.873</td><td>.153</td><td>.669</td><td>.523</td><td>.486</td><td>.270</td><td>.361</td><td>
<bold>.008</bold>
</td><td>.989</td><td>.503</td><td>.503</td><td>
<bold>.001</bold>
</td><td>.605</td><td>.669</td><td>.527</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>
<bold>20</bold>
</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">cingulum (hippocampus) R</td><td>r</td><td>.196</td><td>.095</td><td>.036</td><td>&#x02212;.029</td><td>&#x02212;.202</td><td>&#x02212;.203</td><td>.041</td><td>&#x02212;.204</td><td>&#x02212;.268</td><td>&#x02212;.185</td><td>&#x02212;.166</td><td>&#x02212;.087</td><td>
<bold>.543</bold>
<sup><bold>*</bold></sup>
</td><td>.084</td><td>.048</td><td>&#x02212;.084</td><td>.370</td><td>&#x02212;.068</td><td>&#x02212;.001</td><td>.382</td></tr><tr><td>p</td><td>.395</td><td>.682</td><td>.878</td><td>.900</td><td>.380</td><td>.378</td><td>.862</td><td>.376</td><td>.240</td><td>.422</td><td>.483</td><td>.715</td><td>
<bold>.013</bold>
</td><td>.724</td><td>.839</td><td>.724</td><td>.109</td><td>.816</td><td>.998</td><td>.178</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">cingulum (hippocampus) L</td><td>r</td><td>.187</td><td>&#x02212;.183</td><td>&#x02212;.229</td><td>.141</td><td>&#x02212;.064</td><td>&#x02212;.220</td><td>&#x02212;.104</td><td>&#x02212;.050</td><td>&#x02212;.130</td><td>&#x02212;.080</td><td>&#x02212;.150</td><td>.100</td><td>.291</td><td>.141</td><td>.061</td><td>.046</td><td>.403</td><td>&#x02212;.215</td><td>.170</td><td>&#x02212;.035</td></tr><tr><td>p</td><td>.417</td><td>.426</td><td>.318</td><td>.541</td><td>.784</td><td>.339</td><td>.655</td><td>.830</td><td>.574</td><td>.730</td><td>.527</td><td>.676</td><td>.214</td><td>.553</td><td>.797</td><td>.848</td><td>.078</td><td>.461</td><td>.562</td><td>.905</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">fornix stria terminalis R</td><td>r</td><td>
<bold>.451</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.032</td><td>.097</td><td>.031</td><td>&#x02212;.061</td><td>&#x02212;.043</td><td>&#x02212;.115</td><td>.070</td><td>&#x02212;.252</td><td>&#x02212;.027</td><td>&#x02212;.059</td><td>&#x02212;.056</td><td>
<bold>.668</bold>
<sup><bold>**</bold></sup>
</td><td>.014</td><td>.088</td><td>.013</td><td>.357</td><td>.219</td><td>&#x02212;.132</td><td>
<bold>.561</bold>
<sup><bold>*</bold></sup>
</td></tr><tr><td>p</td><td>
<bold>.040</bold>
</td><td>.892</td><td>.675</td><td>.893</td><td>.794</td><td>.852</td><td>.618</td><td>.763</td><td>.271</td><td>.909</td><td>.805</td><td>.813</td><td>
<bold>.001</bold>
</td><td>.955</td><td>.711</td><td>.956</td><td>.122</td><td>.451</td><td>.654</td><td>
<bold>.037</bold>
</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">fornix stria terminalis L</td><td>r</td><td>.267</td><td>.103</td><td>.084</td><td>.104</td><td>.127</td><td>.371</td><td>&#x02212;.198</td><td>.159</td><td>&#x02212;.006</td><td>.182</td><td>&#x02212;.312</td><td>&#x02212;.136</td><td>
<bold>.472</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.147</td><td>&#x02212;.119</td><td>&#x02212;.138</td><td>
<bold>.581</bold>
<sup><bold>**</bold></sup>
</td><td>.206</td><td>.171</td><td>.429</td></tr><tr><td>p</td><td>.243</td><td>.656</td><td>.716</td><td>.652</td><td>.583</td><td>.098</td><td>.391</td><td>.491</td><td>.980</td><td>.430</td><td>.180</td><td>.569</td><td>
<bold>.036</bold>
</td><td>.537</td><td>.618</td><td>.563</td><td>
<bold>.007</bold>
</td><td>.481</td><td>.559</td><td>.126</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior longitudinal fasciculus R</td><td>r</td><td>&#x02212;.025</td><td>.033</td><td>&#x02212;.121</td><td>&#x02212;.270</td><td>.052</td><td>.310</td><td>&#x02212;.173</td><td>&#x02212;.117</td><td>&#x02212;.151</td><td>&#x02212;.087</td><td>&#x02212;.061</td><td>.074</td><td>.361</td><td>.200</td><td>.105</td><td>.201</td><td>
<bold>.483</bold>
<sup><bold>*</bold></sup>
</td><td>.061</td><td>.116</td><td>.420</td></tr><tr><td>p</td><td>.913</td><td>.888</td><td>.603</td><td>.237</td><td>.821</td><td>.172</td><td>.453</td><td>.614</td><td>.514</td><td>.707</td><td>.798</td><td>.757</td><td>.118</td><td>.397</td><td>.658</td><td>.396</td><td>
<bold>.031</bold>
</td><td>.835</td><td>.692</td><td>.135</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior longitudinal fasciculus L</td><td>r</td><td>&#x02212;.262</td><td>.218</td><td>&#x02212;.103</td><td>&#x02212;.147</td><td>.228</td><td>.260</td><td>.123</td><td>&#x02212;.033</td><td>.233</td><td>.107</td><td>.099</td><td>&#x02212;.007</td><td>.020</td><td>.311</td><td>.025</td><td>.295</td><td>.091</td><td>.132</td><td>.412</td><td>.287</td></tr><tr><td>p</td><td>.252</td><td>.343</td><td>.658</td><td>.524</td><td>.320</td><td>.256</td><td>.595</td><td>.887</td><td>.310</td><td>.643</td><td>.679</td><td>.978</td><td>.933</td><td>.183</td><td>.917</td><td>.207</td><td>.703</td><td>.652</td><td>.143</td><td>.320</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior front occipital fasciculus R</td><td>r</td><td>&#x02212;.260</td><td>.213</td><td>.212</td><td>.003</td><td>&#x02212;.117</td><td>.328</td><td>.135</td><td>&#x02212;.163</td><td>&#x02212;.016</td><td>.054</td><td>&#x02212;.136</td><td>&#x02212;.261</td><td>&#x02212;.095</td><td>.126</td><td>&#x02212;.144</td><td>&#x02212;.435</td><td>&#x02212;.036</td><td>&#x02212;.248</td><td>&#x02212;.156</td><td>.370</td></tr><tr><td>p</td><td>.255</td><td>.354</td><td>.357</td><td>.991</td><td>.613</td><td>.147</td><td>.559</td><td>.479</td><td>.945</td><td>.817</td><td>.567</td><td>.266</td><td>.689</td><td>.596</td><td>.546</td><td>.056</td><td>.881</td><td>.392</td><td>.595</td><td>.192</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">superior front occipital fasciculus L</td><td>r</td><td>
<bold>&#x02212;.484</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.185</td><td>&#x02212;.129</td><td>&#x02212;.116</td><td>&#x02212;.135</td><td>.398</td><td>&#x02212;.085</td><td>&#x02212;.114</td><td>&#x02212;.009</td><td>&#x02212;.023</td><td>&#x02212;.220</td><td>&#x02212;.040</td><td>&#x02212;.397</td><td>.145</td><td>.188</td><td>&#x02212;.051</td><td>
<bold>&#x02212;.494</bold>
<sup><bold>*</bold></sup>
</td><td>.050</td><td>&#x02212;.053</td><td>.196</td></tr><tr><td>p</td><td>
<bold>.026</bold>
</td><td>.422</td><td>.577</td><td>.617</td><td>.558</td><td>.074</td><td>.715</td><td>.622</td><td>.970</td><td>.922</td><td>.350</td><td>.868</td><td>.083</td><td>.541</td><td>.428</td><td>.831</td><td>
<bold>.027</bold>
</td><td>.866</td><td>.858</td><td>.503</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">uncinate fasciculus R</td><td>r</td><td>.286</td><td>.159</td><td>.047</td><td>.004</td><td>.133</td><td>&#x02212;.072</td><td>&#x02212;.054</td><td>&#x02212;.038</td><td>&#x02212;.044</td><td>&#x02212;.017</td><td>.122</td><td>.020</td><td>
<bold>.489</bold>
<sup><bold>*</bold></sup>
</td><td>.366</td><td>&#x02212;.045</td><td>.104</td><td>
<bold>.485</bold>
<sup><bold>*</bold></sup>
</td><td>.064</td><td>.372</td><td>.496</td></tr><tr><td>p</td><td>.210</td><td>.490</td><td>.838</td><td>.987</td><td>.565</td><td>.756</td><td>.818</td><td>.871</td><td>.848</td><td>.941</td><td>.608</td><td>.934</td><td>
<bold>.029</bold>
</td><td>.113</td><td>.849</td><td>.662</td><td>
<bold>.030</bold>
</td><td>.827</td><td>.191</td><td>.071</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">uncinate fasciculus L</td><td>r</td><td>.187</td><td>.271</td><td>.170</td><td>.167</td><td>.096</td><td>.027</td><td>.157</td><td>.153</td><td>.048</td><td>.198</td><td>.045</td><td>&#x02212;.263</td><td>.219</td><td>.223</td><td>&#x02212;.136</td><td>&#x02212;.049</td><td>
<bold>.484</bold>
<sup><bold>*</bold></sup>
</td><td>&#x02212;.032</td><td>.291</td><td>.298</td></tr><tr><td>p</td><td>.416</td><td>.234</td><td>.462</td><td>.470</td><td>.678</td><td>.908</td><td>.496</td><td>.508</td><td>.836</td><td>.390</td><td>.850</td><td>.263</td><td>.355</td><td>.344</td><td>.568</td><td>.837</td><td>
<bold>.031</bold>
</td><td>.913</td><td>.313</td><td>.300</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">tapetum R</td><td>r</td><td>.128</td><td>&#x02212;.075</td><td>&#x02212;.095</td><td>&#x02212;.280</td><td>.302</td><td>.288</td><td>&#x02212;.088</td><td>&#x02212;.211</td><td>&#x02212;.117</td><td>&#x02212;.043</td><td>.046</td><td>.021</td><td>.185</td><td>.161</td><td>&#x02212;.196</td><td>&#x02212;.144</td><td>&#x02212;.155</td><td>&#x02212;.066</td><td>&#x02212;.242</td><td>.176</td></tr><tr><td>p</td><td>.580</td><td>.745</td><td>.683</td><td>.219</td><td>.183</td><td>.206</td><td>.705</td><td>.359</td><td>.612</td><td>.853</td><td>.848</td><td>.930</td><td>.436</td><td>.498</td><td>.408</td><td>.545</td><td>.514</td><td>.822</td><td>.404</td><td>.548</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr><tr><td rowspan="3">tapetum L</td><td>r</td><td>.077</td><td>.106</td><td>.021</td><td>.151</td><td>.054</td><td>.426</td><td>.018</td><td>&#x02212;.023</td><td>.029</td><td>.197</td><td>.107</td><td>&#x02212;.172</td><td>&#x02212;.100</td><td>&#x02212;.130</td><td>&#x02212;.339</td><td>&#x02212;.367</td><td>.117</td><td>&#x02212;.495</td><td>&#x02212;.294</td><td>&#x02212;.259</td></tr><tr><td>p</td><td>.740</td><td>.648</td><td>.928</td><td>.515</td><td>.817</td><td>.054</td><td>.940</td><td>.920</td><td>.902</td><td>.392</td><td>.652</td><td>.468</td><td>.674</td><td>.584</td><td>.144</td><td>.111</td><td>.624</td><td>.072</td><td>.307</td><td>.370</td></tr><tr><td>n</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>21</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>20</td><td>14</td><td>14</td><td>14</td></tr></tbody></table><table-wrap-foot><p>r, Pearson&#x02019;s correlation coefficient; *. <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 **. <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; <italic>R</italic> right, <italic>L</italic> left, <italic>PANSS</italic> Positive and Negative Syndrome Scale, <italic>SANS</italic> Scale for the Assessment of Negative Symptoms, <italic>BACS</italic> Brief Assessment of Cognition in Schizophrenia, <italic>VM</italic> verbal memory, <italic>DS</italic> digit sequencing task, <italic>TM</italic> token motor task, <italic>SC</italic> symbolic coding, <italic>VFC</italic> verbal fluency of category, <italic>VFL</italic> verbal fluency of letter, <italic>TOL</italic> tower of London, <italic>EQS</italic> Emotional Intelligence Scale, <italic>intra</italic> intrapersonal domain, <italic>inter</italic> interpersonal domain, <italic>situa</italic> situational domain; Data in bold indicate they are significant values</p></table-wrap-foot></table-wrap>
</p><p id="Par63">In PANSS-G, an inverse correlation with FA of the splenium of the corpus callosum was noted (the more grade of improvement by DCS was associated with higher FA), and a positive correlation with FA of the posterior thalamic radiation left (L) was noted (the more grade of improvement was associated with lower FA).</p><p id="Par64">In SANS-IV, a positive correlation with FA of the posterior thalamic radiation L was noted (the more grade of improvement was associated with lower FA).</p><p id="Par65">In BACS-TM, positive correlations with FA of the following 4 regions were noted: the sagittal stratum L, cingulum (cingulate gyrus) right (R), cingulum (cingulate gyrus) L, and fornix stria terminalis R (the more grade of improvement was associated with higher FA).</p><p id="Par66">In BACS-TOL, positive correlations with FA of the following 5 regions were noted: the genu of corpus callosum, external capsule L, cingulum (cingulate gyrus) R, cingulum (cingulate gyrus) L, and fornix stria terminalis L (the more grade of improvement was associated with higher FA).</p><p id="Par67">Of these significant correlations, if the 3 EOS patients were excluded from the analysis, the correlations between BACS-TM and cingulum (cingulate gyrus) R and BACS-TOL and fornix stria terminalis L turned non-significant in the <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01 criteria (<italic>p</italic>&#x000a0;=&#x000a0;0.011 and 0.016, respectively).</p></sec><sec id="Sec20"><title>Discussion</title><p id="Par68">The main finding of this study was that DCS did not improve positive symptoms, negative symptoms, or cognitive dysfunction of schizophrenia, and these findings were consistent with most preceding studies concluding that DCS is ineffective for positive symptoms. Regarding negative symptoms, the findings were inconsistent with some preceding studies in which improvement by DCS was observed [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], but consistent with other preceding studies in which no improvement by DCS was observed [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>] or the condition aggravated [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Fewer studies evaluated cognitive dysfunction, but the condition was unchanged [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] excluding a study reporting an improvement [<xref ref-type="bibr" rid="CR6">6</xref>], being consistent with our study. In one meta-analysis including 7 double-blind placebo controlled studies [<xref ref-type="bibr" rid="CR27">27</xref>], DCS did not improve any domain of symptoms, being consistent with our study. However, we can&#x02019;t exclude the possibility that our study failed to demonstrate significant main effects due to the lack of statistical power.</p><p id="Par69">It is possible that the absence of the effect of DCS in this study may have been due to the narrow therapeutic window of DCS. In a dose finding study in which DCS was administered to 8 schizophrenia patients at 15, 50, and 250&#x000a0;mg, negative symptoms were most markedly improved at 50&#x000a0;mg [<xref ref-type="bibr" rid="CR6">6</xref>], whereas symptoms aggravated when DCS was administered at 100&#x000a0;mg or higher [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. It was assumed that since DCS is a partial agonist, it competes with endogenous glycine for the NMDA receptor glycine binding site acting as an antagonist. This was the initial study involving individuals of Japanese descent, and no Japanese individual may have been included in preceding studies including the dose finding study. It is possible that DCS 50&#x000a0;mg is not an optimum dose for Japanese and it may not have changed symptoms in this study.</p><p id="Par70">DCS was administered in addition to antipsychotic drugs that the patients usually took. In preceding clinical studies, when DCS was administered to patients usually treated with clozapine, negative symptoms aggravated [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. It has also been reported that the grade of improvement of the negative symptom score was greater in patients usually treated with typical than atypical antipsychotic drugs [<xref ref-type="bibr" rid="CR16">16</xref>]. In the current study, no subject was medicated with clozapine but most subjects were medicated with atypical antipsychotic drugs, suggesting that DCS did not exhibit a significant effect on negative symptoms in appearance.</p><p id="Par71">DCS was administered at 50&#x000a0;mg/day daily for 6&#x000a0;weeks, but no improvement of cognitive dysfunction was noted. According to Goff et al. [<xref ref-type="bibr" rid="CR11">11</xref>], DCS administered at 50&#x000a0;mg weekly for 8&#x000a0;weeks did not improve overall cognitive function, but improvement was observed in a memory reconstruction task 7&#x000a0;days after a single administration of DCS. Regarding the cognitive function, repeated daily administration of DCS may cause desensitization of the NMDA receptor. In animal model, desensitization was observed with repeated daily administration of DCS [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Another evidence suggest that elevated co-agonists of glycine recognition site facilitate the internalization of NMDA receptor from the cell surface [<xref ref-type="bibr" rid="CR30">30</xref>], representing its desensitization. Since DCS was administered daily repeatedly in our study, it may have caused the desensitization resulting in the absence of the effect of DCS on cognitive dysfunction.</p><p id="Par72">The influence of onset age on the DCS-effect was investigated in the secondary analysis, in which the score was mostly aggravated in the EOS group compared with that in the non-EOS group (i.e., the PANSS and SANS scores increased and the BACS and EQS scores decreased) (Table <xref rid="Tab4" ref-type="table">4</xref>), and aggravation of the PANSS score of negative symptoms in the EOS group was significantly different from that in the non-EOS group. Generally, early-onset schizophrenia (EOS) is intractable and the prognosis is poor compared with non-early-onset schizophrenia (non-EOS). In addition, in our previous clinical genetic study in consideration of the onset age, gene expression related to glutamate neurotransmission was different between EOS and non-EOS [<xref ref-type="bibr" rid="CR31">31</xref>]. Findings observed in these and our studies suggested that heterogeneity of the system related to glutamate neurotransmission appears as a differences in the onset age of schizophrenia and influences response to treatment. However, the findings of the current study might be statistically limited due to the small number of EOS (<italic>n</italic>&#x000a0;=&#x000a0;6) and unbalanced distribution between EOS and non-EOS (<italic>n</italic>&#x000a0;=&#x000a0;30).</p><p id="Par73">By MR-DTI, evidence of altered FA in brain regions of the focus of our study has been accumulated, i.e., decreased FA in genu and splenium of corpus callosum has been reported in patients with schizophrenia [<xref ref-type="bibr" rid="CR32">32</xref>]. Similarly, bilaterally reduced FA was demonstrated in both anterior and posterior cingulum bundles, and suggested associations between FA and the symptomatology of schizophrenia [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Altered FA was reported in brain regions including sagittal stratum and external capsule in suicide attempters with schizophrenia [<xref ref-type="bibr" rid="CR35">35</xref>]. Reduced FA and increased MD were found in the fornix of patients with schizophrenia, and increased MD was associated with performance in cognitive tasks [<xref ref-type="bibr" rid="CR36">36</xref>]. Although no physiological or pathophysiological significance of FA values has been established, it is assumed to be related to changes in the density and damage of the white matter. In the current study, a symptom-site-specific correlation was noted between the treatment effect of DCS and FA. The better treatment effect of DCS on BACS was observed when FA was higher in the sagittal stratum, cingulum, fornix stria terminalis, genu of corpus callosum, and external capsule, and the better treatment effect on PANSS-G was observed when FA of the splenium of corpus callosum was higher. In contrast, the better treatment effect of DCS on PANSS-G and SANS-IV was observed when FA was lower in the posterior thalamic radiation (left). To our knowledge, there is no study that has investigated associations between treatment effect of DCS and white matter integrity. A study reporting that clozapine treatment increased FA in various brain regions in patients with schizophrenia is suggestive to the findings of our study [<xref ref-type="bibr" rid="CR37">37</xref>]. Although our study did not examine changes of FA by DCS treatment per se, changes in cells or molecules in the white matter in the specific brain regions or the grade of subsequent abnormalities of anatomical and functional connectivity between specific brain regions may influence the treatment effect of DCS. Possible aspects of interpreting our findings include that: (1) DCS improves the cognitive function and PANSS-G when the tract is retained at a specific level in brain regions other than the posterior thalamic radiation described above, (2) changes in connectivity with a part of the cortex closely connected with the posterior thalamic radiation through fibers is related the DCS action, and (3) DCS treatment possibly improved the FA of, e.g. thalamic radiation, where an asymmetric alteration in the white matter integrity was demonstrated [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec21"><title>Conclusion</title><p id="Par74">In conclusion, DCS did not improve positive symptoms, negative symptoms, or cognitive dysfunction in schizophrenia. It was suggested that response to DCS is influenced by heterogeneity derived from differences in the onset age and white matter integrity.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AIMS</term><def><p id="Par6">Abnormal Involuntary Movement Scale</p></def></def-item><def-item><term>BACS</term><def><p id="Par7">Brief Assessment of Cognition in Schizophrenia</p></def></def-item><def-item><term>CPZ</term><def><p id="Par8">chlorpromazine</p></def></def-item><def-item><term>CREST</term><def><p id="Par9">Core Research for Evolutional Science and Technology</p></def></def-item><def-item><term>DCS</term><def><p id="Par10">D-cycloserine</p></def></def-item><def-item><term>DIEPSS</term><def><p id="Par11">Drug Induced Extra-Pyramidal Symptoms Scale</p></def></def-item><def-item><term>DS</term><def><p id="Par12">digit sequencing task</p></def></def-item><def-item><term>DSM</term><def><p id="Par13">Diagnostic and Statistical Manual of Mental Disorders</p></def></def-item><def-item><term>DTI</term><def><p id="Par14">diffusion tensor imaging</p></def></def-item><def-item><term>EOS</term><def><p id="Par15">early-onset</p></def></def-item><def-item><term>EQS</term><def><p id="Par16">Emotional Intelligence Scale</p></def></def-item><def-item><term>FA</term><def><p id="Par17">fractional anisotropy</p></def></def-item><def-item><term>FA, MD, AD, RD maps</term><def><p id="Par18">fractional anisotropy, mean diffusivity, axial diffusivity, radial diffusivity maps</p></def></def-item><def-item><term>FDT</term><def><p id="Par19">FMRIB&#x02019;s Diffusion Toolbox</p></def></def-item><def-item><term>FSL</term><def><p id="Par20">FMRIB Software Library</p></def></def-item><def-item><term>G</term><def><p id="Par21">general psychopathology</p></def></def-item><def-item><term>GAF</term><def><p id="Par22">Global Assessment of Functioning</p></def></def-item><def-item><term>JCDSS</term><def><p id="Par23">Japanese version of the Calgary Depression Scale for Schizophrenia</p></def></def-item><def-item><term>MANCOVA</term><def><p id="Par24">multivariate analysis of covariance</p></def></def-item><def-item><term>MR</term><def><p id="Par25">magnetic resonance</p></def></def-item><def-item><term>N</term><def><p id="Par26">negative symptoms</p></def></def-item><def-item><term>NMDA receptor</term><def><p id="Par27">N-Methyl-D-aspartate-type glutamate receptor</p></def></def-item><def-item><term>P</term><def><p id="Par28">positive symptoms</p></def></def-item><def-item><term>PANSS</term><def><p id="Par29">Positive and Negative Syndrome Scale</p></def></def-item><def-item><term>PCB</term><def><p id="Par30">placebo</p></def></def-item><def-item><term>RM-ANCOVA</term><def><p id="Par31">repeated-measures of analysis of covariance</p></def></def-item><def-item><term>ROI</term><def><p id="Par32">region of interest</p></def></def-item><def-item><term>SANS</term><def><p id="Par33">Scale for the Assessment of Negative Symptoms</p></def></def-item><def-item><term>SC</term><def><p id="Par34">symbolic coding</p></def></def-item><def-item><term>TBSS</term><def><p id="Par35">Tract based spatial statistics</p></def></def-item><def-item><term>TM</term><def><p id="Par36">token motor task</p></def></def-item><def-item><term>TOL</term><def><p id="Par37">tower of London</p></def></def-item><def-item><term>VFC</term><def><p id="Par38">verbal fluency of category</p></def></def-item><def-item><term>VFL</term><def><p id="Par39">verbal fluency of letter</p></def></def-item><def-item><term>VM</term><def><p id="Par40">verbal memory</p></def></def-item></def-list></glossary><ack><p>The authors would like to thank all the participants and the mental health care workers involved in this study.</p><sec id="FPar1"><title>Funding</title><p id="Par75">This work was supported by the CREST (Core Research for Evolutional Science and Technology) program and Grant-in-Aid for Scientific Research (B) (Numbers 19390302 and 21390330) funded by and the Ministry of Education, Culture, Sports, Science and Technology of Japan.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par76">The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>KT and AU had major roles in the design and promotion of the study, oversaw the data collection, contributed to the data analysis, and had major roles in writing the paper. MI and AK analyzed and interpreted the patient data regarding the MRI diffusion tensor imaging. HA, KN, NY, KO, KS, MTam, MN, MO, KA and TO recruited the patients and collected clinical data. MTom had a major role in the statistical analysis. SI quantitated the plasma concentrations of DCS. YI and MY prepared capsules containing actual drug or placebo and randomized allocation of the capsules, independent on their clinical application and assessment. TN conceived, designed and directed this project, and wrote the final version of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par77">This study was performed after approval by the Ethics Committee of each institution (Institutional Review Board of Tokyo Medical and Dental University Medical Hospital (No. 17&#x02013;14), Research Ethics Committee of National Center of Neurology and Psychiatry (A2010&#x02013;013), Ethics Committee of Tokushima University Hospital (No. 1154&#x02013;1), Institutional Review Board of Haryugaoka Hospital (No. 2), Ethics Committee of Ohmiya Kousei Hospital (No. 5)). Prior to study initiation, the study was sufficiently explained orally and using documents to all subjects and/or their families and voluntary written consent was obtained.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par78">Consent for publication was included in the consent for study participation.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par79">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par80">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Balla</surname><given-names>A</given-names></name><name><surname>Burch</surname><given-names>S</given-names></name><name><surname>Suckow</surname><given-names>R</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Sershen</surname><given-names>H</given-names></name></person-group><article-title>Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists</article-title><source>Neuropsychopharmacology</source><year>2004</year><volume>29</volume><issue>2</issue><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300313</pub-id><pub-id pub-id-type="pmid">14560321</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Tanii</surname><given-names>Y</given-names></name><name><surname>Umino</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>A</given-names></name><name><surname>Hata</surname><given-names>N</given-names></name><name><surname>Takashima</surname><given-names>M</given-names></name><name><surname>Shirayama</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name></person-group><article-title>Phencyclidine, NMDA receptor and schizophrenia</article-title><source>Yakubutsu Seishin Kodo</source><year>1991</year><volume>11</volume><issue>1</issue><fpage>65</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">1831947</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group><article-title>Glutamate as a therapeutic target in psychiatric disorders</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><issue>11</issue><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001551</pub-id><pub-id pub-id-type="pmid">15278097</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>GE</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Chong</surname><given-names>MY</given-names></name></person-group><article-title>D-alanine added to antipsychotics for the treatment of schizophrenia</article-title><source>Biol Psychiatry</source><year>2006</year><volume>59</volume><issue>3</issue><fpage>230</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.06.032</pub-id><pub-id pub-id-type="pmid">16154544</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hood</surname><given-names>WF</given-names></name><name><surname>Compton</surname><given-names>RP</given-names></name><name><surname>Monahan</surname><given-names>JB</given-names></name></person-group><article-title>D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics</article-title><source>Neurosci Lett</source><year>1989</year><volume>98</volume><issue>1</issue><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(89)90379-0</pub-id><pub-id pub-id-type="pmid">2540460</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Manoach</surname><given-names>DS</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group><article-title>Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia</article-title><source>Am J Psychiatry</source><year>1995</year><volume>152</volume><issue>8</issue><fpage>1213</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1176/ajp.152.8.1213</pub-id><pub-id pub-id-type="pmid">7625475</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Manoach</surname><given-names>DS</given-names></name><name><surname>Flood</surname><given-names>J</given-names></name><name><surname>Darby</surname><given-names>DG</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group><article-title>D-cycloserine added to clozapine for patients with schizophrenia</article-title><source>Am J Psychiatry</source><year>1996</year><volume>153</volume><issue>12</issue><fpage>1628</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1176/ajp.153.12.1628</pub-id><pub-id pub-id-type="pmid">8942463</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Henderson</surname><given-names>DC</given-names></name><name><surname>Evins</surname><given-names>AE</given-names></name><name><surname>Amico</surname><given-names>E</given-names></name></person-group><article-title>A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia</article-title><source>Biol Psychiatry</source><year>1999</year><volume>45</volume><issue>4</issue><fpage>512</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(98)00367-9</pub-id><pub-id pub-id-type="pmid">10071726</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Levitt</surname><given-names>J</given-names></name><name><surname>Amico</surname><given-names>E</given-names></name><name><surname>Manoach</surname><given-names>D</given-names></name><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Hayden</surname><given-names>DL</given-names></name><name><surname>McCarley</surname><given-names>R</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group><article-title>A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia</article-title><source>Arch Gen Psychiatry</source><year>1999</year><volume>56</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.56.1.21</pub-id><pub-id pub-id-type="pmid">9892252</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Herz</surname><given-names>L</given-names></name><name><surname>Posever</surname><given-names>T</given-names></name><name><surname>Shih</surname><given-names>V</given-names></name><name><surname>Tsai</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>DC</given-names></name><name><surname>Freudenreich</surname><given-names>O</given-names></name><name><surname>Evins</surname><given-names>AE</given-names></name><name><surname>Yovel</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients</article-title><source>Psychopharmacology</source><year>2005</year><volume>179</volume><issue>1</issue><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1007/s00213-004-2032-2</pub-id><pub-id pub-id-type="pmid">15502972</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Cather</surname><given-names>C</given-names></name><name><surname>Gottlieb</surname><given-names>JD</given-names></name><name><surname>Evins</surname><given-names>AE</given-names></name><name><surname>Walsh</surname><given-names>J</given-names></name><name><surname>Raeke</surname><given-names>L</given-names></name><name><surname>Otto</surname><given-names>MW</given-names></name><name><surname>Schoenfeld</surname><given-names>D</given-names></name><name><surname>Green</surname><given-names>MF</given-names></name></person-group><article-title>Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study</article-title><source>Schizophr Res</source><year>2008</year><volume>106</volume><issue>2&#x02013;3</issue><fpage>320</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2008.08.012</pub-id><pub-id pub-id-type="pmid">18799288</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Hijman</surname><given-names>R</given-names></name><name><surname>van der Linden</surname><given-names>JA</given-names></name><name><surname>Westenberg</surname><given-names>HG</given-names></name><name><surname>van Ree</surname><given-names>JM</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name></person-group><article-title>Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients</article-title><source>Biol Psychiatry</source><year>1996</year><volume>40</volume><issue>12</issue><fpage>1298</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(96)00311-3</pub-id><pub-id pub-id-type="pmid">8959296</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Evenblij</surname><given-names>CN</given-names></name><name><surname>van Loon</surname><given-names>BJ</given-names></name><name><surname>Maas</surname><given-names>MF</given-names></name><name><surname>van der Geld</surname><given-names>MA</given-names></name><name><surname>Wynne</surname><given-names>HJ</given-names></name><name><surname>van Ree</surname><given-names>JM</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name></person-group><article-title>D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study</article-title><source>Neuropsychopharmacology</source><year>1999</year><volume>21</volume><issue>2</issue><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(99)00014-7</pub-id><pub-id pub-id-type="pmid">10432468</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Ermilov</surname><given-names>M</given-names></name><name><surname>Silipo</surname><given-names>G</given-names></name><name><surname>Shimoni</surname><given-names>J</given-names></name></person-group><article-title>Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia</article-title><source>Int J Neuropsychopharmacol</source><year>1998</year><volume>1</volume><issue>2</issue><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1017/S1461145798001242</pub-id><pub-id pub-id-type="pmid">11281957</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Ermilov</surname><given-names>M</given-names></name><name><surname>Shimoni</surname><given-names>J</given-names></name><name><surname>Shapira</surname><given-names>B</given-names></name><name><surname>Silipo</surname><given-names>G</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group><article-title>Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><issue>3</issue><fpage>480</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.3.480</pub-id><pub-id pub-id-type="pmid">11870017</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evins</surname><given-names>AE</given-names></name><name><surname>Amico</surname><given-names>E</given-names></name><name><surname>Posever</surname><given-names>TA</given-names></name><name><surname>Toker</surname><given-names>R</given-names></name><name><surname>Goff</surname><given-names>DC</given-names></name></person-group><article-title>D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia</article-title><source>Schizophr Res</source><year>2002</year><volume>56</volume><issue>1&#x02013;2</issue><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(01)00220-1</pub-id><pub-id pub-id-type="pmid">12084415</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascella</surname><given-names>NG</given-names></name><name><surname>Macciardi</surname><given-names>F</given-names></name><name><surname>Cavallini</surname><given-names>C</given-names></name><name><surname>Smeraldi</surname><given-names>E</given-names></name></person-group><article-title>D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study</article-title><source>J Neural Transm Gen Sect</source><year>1994</year><volume>95</volume><issue>2</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1007/BF01276429</pub-id><pub-id pub-id-type="pmid">7865165</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosse</surname><given-names>RB</given-names></name><name><surname>Fay-McCarthy</surname><given-names>M</given-names></name><name><surname>Kendrick</surname><given-names>K</given-names></name><name><surname>Davis</surname><given-names>RE</given-names></name><name><surname>Deutsch</surname><given-names>SI</given-names></name></person-group><article-title>D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia</article-title><source>Clin Neuropharmacol</source><year>1996</year><volume>19</volume><issue>5</issue><fpage>444</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1097/00002826-199619050-00008</pub-id><pub-id pub-id-type="pmid">8889288</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>EJ</given-names></name><name><surname>Szilagyi</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>MP</given-names></name><name><surname>Bugarski-Kirola</surname><given-names>D</given-names></name><name><surname>Kunzova</surname><given-names>A</given-names></name><name><surname>Negi</surname><given-names>S</given-names></name><name><surname>Stephanides</surname><given-names>M</given-names></name><name><surname>Efferen</surname><given-names>TR</given-names></name><name><surname>Angrist</surname><given-names>B</given-names></name><name><surname>Peselow</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of D-cycloserine on negative symptoms in schizophrenia</article-title><source>Schizophr Res</source><year>2004</year><volume>71</volume><issue>2&#x02013;3</issue><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2004.03.013</pub-id><pub-id pub-id-type="pmid">15474895</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>RW</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name><name><surname>Marder</surname><given-names>SR</given-names></name><name><surname>Schooler</surname><given-names>NR</given-names></name><name><surname>Gold</surname><given-names>JM</given-names></name><name><surname>McMahon</surname><given-names>RP</given-names></name><name><surname>Heresco-Levy</surname><given-names>U</given-names></name><name><surname>Carpenter</surname><given-names>WT</given-names></name></person-group><article-title>The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><issue>10</issue><fpage>1593</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2007.06081358</pub-id><pub-id pub-id-type="pmid">17898352</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veru</surname><given-names>F</given-names></name><name><surname>Jordan</surname><given-names>G</given-names></name><name><surname>Joober</surname><given-names>R</given-names></name><name><surname>Malla</surname><given-names>A</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name></person-group><article-title>Adolescent vs. adult onset of a first episode psychosis: impact on remission of positive and negative symptoms</article-title><source>Schizophr Res</source><year>2016</year><volume>174</volume><issue>1&#x02013;3</issue><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2016.03.035</pub-id><pub-id pub-id-type="pmid">27102425</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stentebjerg-Olesen</surname><given-names>M</given-names></name><name><surname>Pagsberg</surname><given-names>AK</given-names></name><name><surname>Fink-Jensen</surname><given-names>A</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name><name><surname>Jeppesen</surname><given-names>P</given-names></name></person-group><article-title>Clinical characteristics and predictors of outcome of schizophrenia-Spectrum psychosis in children and adolescents: a systematic review</article-title><source>J Child Adolesc Psychopharmacol</source><year>2016</year><volume>26</volume><issue>5</issue><fpage>410</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1089/cap.2015.0097</pub-id><pub-id pub-id-type="pmid">27136403</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dazzan</surname><given-names>P</given-names></name></person-group><article-title>Neuroimaging biomarkers to predict treatment response in schizophrenia: the end of 30 years of solitude?</article-title><source>Dialogues Clin Neurosci</source><year>2014</year><volume>16</volume><issue>4</issue><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">25733954</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Jenkinson</surname><given-names>M</given-names></name><name><surname>Johansen-Berg</surname><given-names>H</given-names></name><name><surname>Rueckert</surname><given-names>D</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name><name><surname>Mackay</surname><given-names>CE</given-names></name><name><surname>Watkins</surname><given-names>KE</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name><name><surname>Cader</surname><given-names>MZ</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data</article-title><source>NeuroImage</source><year>2006</year><volume>31</volume><issue>4</issue><fpage>1487</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.02.024</pub-id><pub-id pub-id-type="pmid">16624579</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemmensen</surname><given-names>L</given-names></name><name><surname>Vernal</surname><given-names>DL</given-names></name><name><surname>Steinhausen</surname><given-names>HC</given-names></name></person-group><article-title>A systematic review of the long-term outcome of early onset schizophrenia</article-title><source>BMC Psychiatry</source><year>2012</year><volume>12</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-12-150</pub-id><pub-id pub-id-type="pmid">22992395</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>RX</given-names></name><name><surname>Iwasato</surname><given-names>T</given-names></name><name><surname>Itohara</surname><given-names>S</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Bettler</surname><given-names>B</given-names></name><name><surname>Miczek</surname><given-names>KA</given-names></name><name><surname>Koide</surname><given-names>T</given-names></name></person-group><article-title>Glutamate input in the dorsal raphe nucleus as a determinant of escalated aggression in male mice</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><issue>16</issue><fpage>6452</fpage><lpage>6463</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2450-14.2015</pub-id><pub-id pub-id-type="pmid">25904796</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>GE</given-names></name><name><surname>Lin</surname><given-names>PY</given-names></name></person-group><article-title>Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis</article-title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><issue>5</issue><fpage>522</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.2174/138161210790361452</pub-id><pub-id pub-id-type="pmid">19909229</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quartermain</surname><given-names>D</given-names></name><name><surname>Mower</surname><given-names>J</given-names></name><name><surname>Rafferty</surname><given-names>MF</given-names></name><name><surname>Herting</surname><given-names>RL</given-names></name><name><surname>Lanthorn</surname><given-names>TH</given-names></name></person-group><article-title>Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention</article-title><source>Eur J Pharmacol</source><year>1994</year><volume>257</volume><issue>1&#x02013;2</issue><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(94)90687-4</pub-id><pub-id pub-id-type="pmid">8082709</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnas</surname><given-names>AS</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>R</given-names></name></person-group><article-title>Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats</article-title><source>Neurobiol Learn Mem</source><year>2005</year><volume>83</volume><issue>3</issue><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2005.01.001</pub-id><pub-id pub-id-type="pmid">15820858</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nong</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>YQ</given-names></name><name><surname>Ju</surname><given-names>W</given-names></name><name><surname>Kalia</surname><given-names>LV</given-names></name><name><surname>Ahmadian</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name><name><surname>Salter</surname><given-names>MW</given-names></name></person-group><article-title>Glycine binding primes NMDA receptor internalization</article-title><source>Nature</source><year>2003</year><volume>422</volume><issue>6929</issue><fpage>302</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/nature01497</pub-id><pub-id pub-id-type="pmid">12646920</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uezato</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Iwayama</surname><given-names>Y</given-names></name><name><surname>Hiraoka</surname><given-names>S</given-names></name><name><surname>Hiraaki</surname><given-names>E</given-names></name><name><surname>Umino</surname><given-names>A</given-names></name><name><surname>Haramo</surname><given-names>E</given-names></name><name><surname>Umino</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name></person-group><article-title>Reduced cortical expression of a newly identified splicing variant of the DLG1 gene in patients with early-onset schizophrenia</article-title><source>Transl Psychiatry</source><year>2015</year><volume>5</volume><pub-id pub-id-type="doi">10.1038/tp.2015.154</pub-id><pub-id pub-id-type="pmid">26440542</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>Diffusion tensor MR imaging evaluation of Callosal abnormalities in schizophrenia: a meta-analysis</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>8</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0161406</pub-id><pub-id pub-id-type="pmid">27536773</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Namiki</surname><given-names>C</given-names></name><name><surname>Hirao</surname><given-names>K</given-names></name><name><surname>Miyata</surname><given-names>J</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name><name><surname>Sawamoto</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Murai</surname><given-names>T</given-names></name></person-group><article-title>Anterior and posterior cingulum abnormalities and their association with psychopathology in schizophrenia: a diffusion tensor imaging study</article-title><source>Schizophr Res</source><year>2007</year><volume>95</volume><issue>1&#x02013;3</issue><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2007.05.044</pub-id><pub-id pub-id-type="pmid">17664062</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Bopp MH, Zollner R, Jansen A, Dietsche B, Krug A, Kircher TT. White matter integrity and symptom dimensions of schizophrenia: a diffusion tensor imaging study. Schizophr Res. 2016;</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Oh</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Bang</surname><given-names>SY</given-names></name><name><surname>Choi</surname><given-names>TK</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group><article-title>White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder</article-title><source>Psychiatry Res</source><year>2016</year><volume>248</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2016.01.011</pub-id><pub-id pub-id-type="pmid">26774424</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>K</given-names></name><name><surname>Yamasue</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>O</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Suga</surname><given-names>M</given-names></name><name><surname>Sekita</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Rogers</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Disrupted integrity of the fornix is associated with impaired memory organization in schizophrenia</article-title><source>Schizophr Res</source><year>2008</year><volume>103</volume><issue>1&#x02013;3</issue><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2008.03.008</pub-id><pub-id pub-id-type="pmid">18442897</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcelik-Eroglu</surname><given-names>E</given-names></name><name><surname>Ertugrul</surname><given-names>A</given-names></name><name><surname>Oguz</surname><given-names>KK</given-names></name><name><surname>Has</surname><given-names>AC</given-names></name><name><surname>Karahan</surname><given-names>S</given-names></name><name><surname>Yazici</surname><given-names>MK</given-names></name></person-group><article-title>Effect of clozapine on white matter integrity in patients with schizophrenia: a diffusion tensor imaging study</article-title><source>Psychiatry Res</source><year>2014</year><volume>223</volume><issue>3</issue><fpage>226</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2014.06.001</pub-id><pub-id pub-id-type="pmid">25012780</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamah</surname><given-names>D</given-names></name><name><surname>Conturo</surname><given-names>TE</given-names></name><name><surname>Harms</surname><given-names>MP</given-names></name><name><surname>Akbudak</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>McMichael</surname><given-names>AR</given-names></name><name><surname>Gado</surname><given-names>MH</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Csernansky</surname><given-names>JG</given-names></name></person-group><article-title>Anterior thalamic radiation integrity in schizophrenia: a diffusion-tensor imaging study</article-title><source>Psychiatry Res</source><year>2010</year><volume>183</volume><issue>2</issue><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2010.04.013</pub-id><pub-id pub-id-type="pmid">20619618</pub-id></element-citation></ref></ref-list></back></article>